BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2005;9:191-211. [DOI: 10.1016/j.cld.2004.12.009] [Cited by in Crossref: 601] [Cited by in F6Publishing: 553] [Article Influence: 35.4] [Reference Citation Analysis]
Number Citing Articles
1 Yang H, Lin M, Xiong FX, Yang Y, Nie X, Zhou RL. Reduced expression of ASS is closely related to clinicopathological features and post-resectional survival of hepatocellular carcinoma. Oncol Lett 2010;1:31-6. [PMID: 22966251 DOI: 10.3892/ol_00000005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Law ST, Li KK, Ho YY. Nephrotoxicity, including acquired Fanconi’s syndrome, caused by adefovir dipivoxil - is there a safe dose? J Clin Pharm Ther. 2012;37:128-131. [PMID: 21714795 DOI: 10.1111/j.1365-2710.2011.01278.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
3 Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38:5366-5383. [PMID: 20423907 DOI: 10.1093/nar/gkq285] [Cited by in Crossref: 685] [Cited by in F6Publishing: 667] [Article Influence: 57.1] [Reference Citation Analysis]
4 Cheng CW, Chow AK, Pang R, Fok EW, Kwong YL, Tse E. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of the antiapoptotic function of survivin. Am J Pathol. 2013;182:765-775. [PMID: 23333752 DOI: 10.1016/j.ajpath.2012.11.034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
5 Farooq M, Wadaan MA. Epigenetic targets in hepatocellular carcinoma cells: identification of chaperone protein complexes with histone deacetylases. Epigenomics 2013;5:501-12. [PMID: 24059797 DOI: 10.2217/epi.13.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Phillips RJ, Helbig KJ, Hoek KHVD, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18(26): 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18.i26.3389] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
7 Choi HS, Kang KM, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol 2021;17:209-15. [PMID: 32757461 DOI: 10.1111/ajco.13361] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Oikonomopoulos G, Aravind P, Sarker D. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? Future Oncology 2016;12:465-76. [DOI: 10.2217/fon.15.341] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
9 Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes. 2014;5:441-445. [PMID: 25006881 DOI: 10.4161/gmic.29599] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
10 Jia Z, Wang L, Liu C, Yu Z, Chai L, Zhao M. Evaluation of α-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn). 2014;18:192-196. [PMID: 25520580 DOI: 10.5114/wo.2014.43157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
11 Zhang Q, Wei L, Yang H, Yang W, Yang Q, Zhang Z, Wu K, Wu J. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection. Cancer Lett 2016;371:107-16. [PMID: 26620707 DOI: 10.1016/j.canlet.2015.11.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
12 Wang RC, Huang CY, Pan TL, Chen WY, Ho CT, Liu TZ, Chang YJ. Proteomic Characterization of Annexin l (ANX1) and Heat Shock Protein 27 (HSP27) as Biomarkers for Invasive Hepatocellular Carcinoma Cells. PLoS One 2015;10:e0139232. [PMID: 26431426 DOI: 10.1371/journal.pone.0139232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
13 Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol 2020;18:457-467.e21. [PMID: 31306800 DOI: 10.1016/j.cgh.2019.07.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
14 Srivastava M, Rungta S, Dixit VK, Shukla SK, Singh TB, Jain AK. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antiviral Res. 2013;100:300-305. [PMID: 24012998 DOI: 10.1016/j.antiviral.2013.08.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
15 Tjia WM, Hu L, Zhang M, Guan X. Characterization of rearrangements involving 4q, 13q and 16q in hepatocellular carcinoma cell lines using region-specific multiplex-FISH probes. Cancer Letters 2007;250:92-9. [DOI: 10.1016/j.canlet.2006.09.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
16 Vitale G, Corona P, Loriga M, Carta A, Paglietti G, Giliberti G, Sanna G, Farci P, Marongiu ME, La Colla P. 5-Acetyl-2-arylbenzimidazoles as antiviral agents. Part 4. European Journal of Medicinal Chemistry 2012;53:83-97. [DOI: 10.1016/j.ejmech.2012.03.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
17 Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2009;53:5134-5140. [PMID: 19770281 DOI: 10.1128/aac.00276-09] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
18 Djokic M, Cemazar M, Bosnjak M, Dezman R, Badovinac D, Miklavcic D, Kos B, Stabuc M, Stabuc B, Jansa R, Popovic P, Smid LM, Sersa G, Trotovsek B. A Prospective Phase II Study Evaluating Intraoperative Electrochemotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3778. [PMID: 33333941 DOI: 10.3390/cancers12123778] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhang YJ, Li H, Wu HC, Shen J, Wang L, Yu MW, Lee PH, Bernard Weinstein I, Santella RM. Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett. 2009;275:277-284. [PMID: 19081673 DOI: 10.1016/j.canlet.2008.10.042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
20 Abdelaziz AO, Nabil MM, Omran DA, Abdelmaksoud AH, Asem N, Shousha HI, Elbaz TM, Leithy R. Hepatocellular Carcinoma Multidisciplinary Clinic-Cairo University (HMC-CU) score: A new simple score for diagnosis of HCC. Arab J Gastroenterol 2020;21:102-5. [PMID: 32439235 DOI: 10.1016/j.ajg.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Yamazaki T, Mori M, Arai S, Tateishi R, Abe M, Ban M, Nishijima A, Maeda M, Asano T, Kai T, Izumino K, Takahashi J, Aoyama K, Harada S, Takebayashi T, Gunji T, Ohnishi S, Seto S, Yoshida Y, Hiasa Y, Koike K, Yamamura K, Inoue K, Miyazaki T. Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. PLoS One 2014;9:e109123. [PMID: 25302503 DOI: 10.1371/journal.pone.0109123] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
22 Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. Gastroenterol Clin North Am. 2016;45:345-358. [PMID: 27261903 DOI: 10.1016/j.gtc.2016.02.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
23 Perryman SV, Sylvester KG. Repair and regeneration: opportunities for carcinogenesis from tissue stem cells. J Cell Mol Med 2006;10:292-308. [PMID: 16796800 DOI: 10.1111/j.1582-4934.2006.tb00400.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
24 Chaves SS, Fischer G, Groeger J, Patel PR, Thompson ND, Teshale EH, Stevenson K, Yano VM, Armstrong GL, Samandari T. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine. 2012;30:1644-1649. [PMID: 22245310 DOI: 10.1016/j.vaccine.2011.12.106] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
25 Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut Liver 2010;4 Suppl 1:S113-8. [PMID: 21103289 DOI: 10.5009/gnl.2010.4.S1.S113] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
26 Zhang DM, Liu JS, Tang MK, Yiu A, Cao HH, Jiang L, Chan JY, Tian HY, Fung KP, Ye WC. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Eur J Pharmacol 2012;692:19-28. [PMID: 22841670 DOI: 10.1016/j.ejphar.2012.06.045] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 6.6] [Reference Citation Analysis]
27 El-serag HB, Lechel A, Rudolph KL. Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 142-56. [DOI: 10.1016/b978-1-4377-0881-3.00010-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Al-Qahtani AA, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, Al-Ashgar HI, Khalaf N, Viswan N, Al-Ahdal MN. Genetic variation at -1878 (rs2596542) in MICA gene region is associated with chronic hepatitis B virus infection in Saudi Arabian patients. Exp Mol Pathol 2013;95:255-8. [PMID: 23994040 DOI: 10.1016/j.yexmp.2013.08.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
29 Mescam M, Kretowski M, Bezy-Wendling J. Multiscale model of liver DCE-MRI towards a better understanding of tumor complexity. IEEE Trans Med Imaging 2010;29:699-707. [PMID: 19758856 DOI: 10.1109/TMI.2009.2031435] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
30 Nguyen K, Van Nguyen T, Shen D, Xia V, Tran D, Banh K, Ruan V, Hu K. Prevalence and Presentation of Hepatitis B and C Virus (HBV and HCV) Infection in Vietnamese Americans via Serial Community Serologic Testing. J Immigrant Minority Health 2015;17:13-20. [DOI: 10.1007/s10903-013-9975-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
31 Chikhale M, Toi PC, Siddaraju N, Ananthakrishnan R. The strength of cytomorphology and efficacy of immuno-cytochemistry in distinguishing hepatocellular carcinoma from its mimics on fine-needle aspiration cytology. Diagn Cytopathol 2021;49:864-75. [PMID: 33929782 DOI: 10.1002/dc.24759] [Reference Citation Analysis]
32 Borie F, Trétarre B, Bouvier A, Faivre J, Binder F, Launoy G, Delafosse P, Tissot J, Peng J, Grosclaude P, Guizard A, Gras-aygon C. Primitive liver cancers: epidemiology and geographical study in France. European Journal of Gastroenterology & Hepatology 2009;21:984-9. [DOI: 10.1097/meg.0b013e3283293783] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
33 Komatsu G, Nonomura T, Sasaki M, Ishida Y, Arai S, Miyazaki T. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease. Exp Anim 2019;68:147-58. [PMID: 30487357 DOI: 10.1538/expanim.18-0108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014;11:e1001770. [PMID: 25536056 DOI: 10.1371/journal.pmed.1001770] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
35 Hu J, Huang ZS, Zhou XH, Hu GY, Qin YQ, Yin YX. Epigenetic effects of microRNAs and development of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(29): 4437-4444 [DOI: 10.11569/wcjd.v22.i29.4437] [Reference Citation Analysis]
36 Higashi M, Yoshimura T, Usui N, Kano Y, Deguchi A, Tanabe K, Uchimura Y, Kuriyama S, Suzuki Y, Masaki T, Ikenaka K. A Potential Serum N-glycan Biomarker for Hepatitis C Virus-Related Early-Stage Hepatocellular Carcinoma with Liver Cirrhosis. Int J Mol Sci 2020;21:E8913. [PMID: 33255418 DOI: 10.3390/ijms21238913] [Reference Citation Analysis]
37 Liu Y, Lin J. Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy. Future Oncol 2011;7:161-4. [PMID: 21345134 DOI: 10.2217/fon.10.183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
38 Thompson KJ, Swan RZ, Iannitti DA, McKillop IH, Sindram D. Diet-induced obesity and ethanol impair progression of hepatocellular carcinoma in a mouse mesenteric vein injection model. Surg Endosc 2013;27:246-55. [PMID: 22806512 DOI: 10.1007/s00464-012-2429-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
39 Almeida-carvalho SR, Gomes-ferraz ML, Loureiro-matos CA, Benedito-silva AE, Carvalho-filho RJ, Renato-perez R, Miziara-gonzalez A, Salzedas-netto AA, Szejnfeld D, D’ippolito G, Pereira-lanzoni V, Souza-silva IS. Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil. Annals of Hepatology 2017;16:255-62. [DOI: 10.5604/16652681.1231586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
40 Bae JS, Kim J, Pasaje CFA, Cheong HS, Lee TH, Koh IS, Lee H, Kim YJ, Shin HD. Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Digestive and Liver Disease 2012;44:849-54. [DOI: 10.1016/j.dld.2012.04.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
41 Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 2011;459:129-139. [PMID: 21713366 DOI: 10.1007/s00428-011-1103-0)] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Tan P, Grundy L, Makary P, Eng KH, Ramsay G, Bekheit M. The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review. Transl Gastroenterol Hepatol 2021;6:54. [PMID: 34805576 DOI: 10.21037/tgh.2020.01.11] [Reference Citation Analysis]
43 Xing M, Sakaria S, Dhanasekaran R, Parekh S, Spivey J, Knechtle SJ, Zhang D, Kim HS. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2017;40:410-420. [PMID: 27900445 DOI: 10.1007/s00270-016-1505-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
44 Morgan TR. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res. 2011;188:85-99. [PMID: 21253791 DOI: 10.1007/978-3-642-10858-7_7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
45 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
46 Richardson KK, Shannon MT. STI screening and treatment in pregnancy. Nurse Pract 2012;37:30-7. [PMID: 23165134 DOI: 10.1097/01.NPR.0000422203.95229.ee] [Reference Citation Analysis]
47 Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis. 2016;5:e273. [PMID: 27918551 DOI: 10.1038/oncsis.2016.77.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Wong Ch, Goh K. Chronic hepatitis B infection and liver cancer. Biomed Imaging Interv J 2006;2:e7. [PMID: 21614253 DOI: 10.2349/biij.2.3.e7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
49 Wu X, Wu J, Xin Z, Wang H, Zhu X, Pan L, Li Z, Li H, Liu Y. A 3' UTR SNP in COL18A1 is associated with susceptibility to HBV related hepatocellular carcinoma in Chinese: three independent case-control studies. PLoS One. 2012;7:e33855. [PMID: 22461898 DOI: 10.1371/journal.pone.0033855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
50 McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res. 2006;136:125-135. [PMID: 17023002 DOI: 10.1016/j.jss.2006.04.013] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
51 Baqai S, Proudfoot J, Xu R, Kane S, Clark M, Gish R. Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patients. BMJ Open Gastroenterol 2015;2:e000030. [PMID: 26462281 DOI: 10.1136/bmjgast-2015-000030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Feng Q, Yu M, Kiviat NB. Molecular biomarkers for cancer detection in blood and bodily fluids. Crit Rev Clin Lab Sci 2006;43:497-560. [PMID: 17050080 DOI: 10.1080/10408360600922632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
53 Ziogas DC, Papadatos-pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O’grady J, Al-khadimi G, Allen N, Heaton N, Ross PJ, Sarker D. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. European Journal of Gastroenterology & Hepatology 2017;29:48-55. [DOI: 10.1097/meg.0000000000000739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
54 Lawless MW, O’Byrne KJ, Gray SG. Targeting oxidative stress in cancer. Expert Opin Ther Targets. 2010;14:1225-1245. [PMID: 20942747 DOI: 10.1517/14728222.2010.526933] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
55 Bekeredjian R, Kroll RD, Fein E, Tinkov S, Coester C, Winter G, Katus HA, Kulaksiz H. Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol 2007;33:1592-8. [PMID: 17618040 DOI: 10.1016/j.ultrasmedbio.2007.05.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
56 Dubel GJ, Soares GM. Regional infusion-radioembolization. Surg Oncol Clin N Am 2008;17:957-85, xii. [PMID: 18722928 DOI: 10.1016/j.soc.2008.04.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Zhu K, Moriarty C, Caplan LS, Levine RS. Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control. 2007;18:315-321. [PMID: 17294291 DOI: 10.1007/s10552-006-0105-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
58 Golob-Schwarzl N, Krassnig S, Toeglhofer AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H, Schicho R, Fickert P, Haybaeck J. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer 2017;83:56-70. [PMID: 28715695 DOI: 10.1016/j.ejca.2017.06.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
59 Lee YB, Lee J, Kim YJ, Yoon J, Lee H. The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection: Therapeutic Vaccination in Chronic Hepatitis B. J Med Virol 2015;87:575-82. [DOI: 10.1002/jmv.24091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
60 Ibrahim GH, Mahmoud MA, Aly NM. Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients. Mol Biol Rep. 2013;40:7069-7075. [PMID: 24186850 DOI: 10.1007/s11033-013-2829-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
61 Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S, Gupta S, Datta S, Chowdhury A, Chatterjee R. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. Int J Cancer. 2016;138:2732-2744. [PMID: 26756996 DOI: 10.1002/ijc.29999] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
62 Avila MA, Lu KP. Hepatitis B Virus X Protein and Pin1 in Liver Cancer: “Les Liaisons Dangereuses”. Gastroenterology 2007;132:1180-3. [DOI: 10.1053/j.gastro.2007.01.061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
63 Kelsh MA, Morimoto L, Lau E. Cancer mortality and oil production in the Amazon Region of Ecuador, 1990-2005. Int Arch Occup Environ Health 2009;82:381-95. [PMID: 18651161 DOI: 10.1007/s00420-008-0345-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
64 Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. neo 2012;60:135-42. [DOI: 10.4149/neo_2013_018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 84] [Article Influence: 7.5] [Reference Citation Analysis]
65 Krishnamurthy P, Brown M, Agrawal S, Short RF. Acute pancreatitis as a complication of trans-arterial chemoembolization of hepatocellular cancer-case report and review of literature. J Gastrointest Oncol 2017;8:E26-30. [PMID: 28280633 DOI: 10.21037/jgo.2017.01.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Burnett NP, Dunki-jacobs EM, Callender GG, Anderson RJ, Scoggins CR, Mcmasters KM, Martin RC. Evaluation of Alpha-fetoprotein Staging System for Hepatocellular Carcinoma in Noncirrhotic Patients. The American Surgeon 2013;79:716-22. [DOI: 10.1177/000313481307900717] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Lin Y, Yan M, Shih Y, Hsieh C. The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma. European Journal of Cancer 2009;45:2041-9. [DOI: 10.1016/j.ejca.2009.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
68 Hassan A, Tsuda Y, Asai A, Yokohama K, Nakamura K, Sujishi T, Ohama H, Tsuchimoto Y, Fukunishi S, Abdelaal UM, Arafa UA, Hassan AT, Kassem AM, Higuchi K. Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients. Mediators Inflamm 2015;2015:608216. [PMID: 26664151 DOI: 10.1155/2015/608216] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
69 Dow M, Pyke RM, Tsui BY, Alexandrov LB, Nakagawa H, Taniguchi K, Seki E, Harismendy O, Shalapour S, Karin M, Carter H, Font-Burgada J. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2018;115:E9879-88. [PMID: 30287485 DOI: 10.1073/pnas.1811029115] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
70 Herzig MC, Hildreth K, Huamani J, Perez M, Goins BA, McMahan CA, Reddick RL, Walter CA. Human O6 -methylguanine-DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice. Mol Carcinog 2013;52:275-85. [PMID: 22213062 DOI: 10.1002/mc.21855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 2012;56:1371-1383. [PMID: 22314424 DOI: 10.1016/j.jhep.2011.11.026] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 15.7] [Reference Citation Analysis]
72 Schiffman SC, Woodall CE, Kooby DA, Martin RC, Staley CA, Egnatashvili V, McMasters KM, Scoggins CR. Factors associated with recurrence and survival following hepatectomy for large hepatocellular carcinoma: a multicenter analysis. J Surg Oncol. 2010;101:105-110. [PMID: 20035538 DOI: 10.1002/jso.21461] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
73 Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology. 2012;56:622-631. [PMID: 22370893 DOI: 10.1002/hep.25679] [Cited by in Crossref: 193] [Cited by in F6Publishing: 192] [Article Influence: 19.3] [Reference Citation Analysis]
74 Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 2009;9:324. [PMID: 19744348 DOI: 10.1186/1471-2407-9-324] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
75 Shimofusa R, Ueda T, Kishimoto T, Nakajima M, Yoshikawa M, Kondo F, Ito H. Magnetic resonance imaging of hepatocellular carcinoma: a pictorial review of novel insights into pathophysiological features revealed by magnetic resonance imaging. Journal of Hepato-Biliary-Pancreatic Sciences 2010;17:583-9. [DOI: 10.1007/s00534-009-0198-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
76 Schneider CM, Dachs GW, Hasser CJ, Choti MA, Dimaio SP, Taylor RH. Robot-Assisted Laparoscopic Ultrasound. In: Navab N, Jannin P, editors. Information Processing in Computer-Assisted Interventions. Berlin: Springer Berlin Heidelberg; 2010. pp. 67-80. [DOI: 10.1007/978-3-642-13711-2_7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
77 Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24 Suppl 2:ii6-14. [PMID: 23715943 DOI: 10.1093/annonc/mdt052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Cardoso BR, Duarte GBS, Reis BZ, Cozzolino SMF. Brazil nuts: Nutritional composition, health benefits and safety aspects. Food Res Int. 2017;100:9-18. [PMID: 28888463 DOI: 10.1016/j.foodres.2017.08.036] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 11.6] [Reference Citation Analysis]
79 Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol. 2015;30:43-50. [PMID: 25168842 DOI: 10.1111/jgh.12728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
80 Ippolito D, Inchingolo R, Grazioli L, Drago SG, Nardella M, Gatti M, Faletti R. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. World J Gastroenterol 2018; 24(23): 2413-2426 [PMID: 29930464 DOI: 10.3748/wjg.v24.i23.2413] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
81 Zhai G, Yang H, Ji X, Xiong F, Su J, McNutt MA, Li X. Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Med Oncol 2012;29:2744-9. [PMID: 22207410 DOI: 10.1007/s12032-011-0139-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
82 Nakamura M, Aoyama A, Salim MT, Okamoto M, Baba M, Miyachi H, Hashimoto Y, Aoyama H. Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton. Bioorganic & Medicinal Chemistry 2010;18:2402-11. [DOI: 10.1016/j.bmc.2010.02.057] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
83 Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Migliore C, Kowalik MA, Ledda-Columbano GM, Giordano S. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology. 2014;59:228-241. [PMID: 23857252 DOI: 10.1002/hep.26616] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 9.6] [Reference Citation Analysis]
84 Woodall CE, Scoggins CR, Loehle J, Ravindra KV, McMasters KM, Martin RC. Hepatic imaging characteristics predict overall survival in hepatocellular carcinoma. Ann Surg Oncol 2007;14:2824-30. [PMID: 17690939 DOI: 10.1245/s10434-007-9525-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
85 Middleton CH, Irving W, Robertson JF, Murray A, Parsy-Kowalska CB, Macdonald IK, McElveen J, Allen J, Healey GF, Thomson BJ. Serum autoantibody measurement for the detection of hepatocellular carcinoma. PLoS One. 2014;9:e103867. [PMID: 25093332 DOI: 10.1371/journal.pone.0103867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
86 Osório FMF, Lauar GM, Lima AS, Vidigal PVT, Ferrari TCA, Couto CA. EPIDEMIOLOGICAL ASPECTS OF HEPATOCELLULAR CARCINOMA IN A REFERRAL CENTER OF MINAS GERAIS, BRAZIL. Arq Gastroenterol 2013;50:97-100. [DOI: 10.1590/s0004-28032013000200015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
87 Wang Y, Jiang J, Ma H, Han J, Sun Z, Liu Z, Xu Z. Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. Tumor Biol 2014;35:7429-33. [DOI: 10.1007/s13277-014-1971-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
88 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015; 7(12): 1708-1717 [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
89 Yi T, Luo H, Qin F, Jiang Q, He S, Wang T, Su J, Song S, Qin X, Qin Y, Zhou X, Huang Z. LncRNA LL22NC03-N14H11.1 promoted hepatocellular carcinoma progression through activating MAPK pathway to induce mitochondrial fission. Cell Death Dis 2020;11:832. [PMID: 33028809 DOI: 10.1038/s41419-020-2584-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Xie HP, Yang HZ, Wu WK, Guan WB, Ke QS, Li YW, Dai M, Xiao GM, Zhang JS, Li YM. Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase. Chin J Integr Med 2014;20:94-100. [PMID: 24619234 DOI: 10.1007/s11655-013-1569-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
91 Wang ZL, Gao S, Li XY, Sun FK, Li F, Fan YC, Wang K. Demethylation of tumor necrosis factor-α converting enzyme promoter associated with high hepatitis B e antigen level in chronic hepatitis B. World J Gastroenterol 2015; 21(27): 8382-8388 [PMID: 26217090 DOI: 10.3748/wjg.v21.i27.8382] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Stagos D, Amoutzias GD, Matakos A, Spyrou A, Tsatsakis AM, Kouretas D. Chemoprevention of liver cancer by plant polyphenols. Food and Chemical Toxicology 2012;50:2155-70. [DOI: 10.1016/j.fct.2012.04.002] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 10.0] [Reference Citation Analysis]
93 You JH, Chan FW. Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opinion on Pharmacotherapy 2008;9:2673-81. [DOI: 10.1517/14656566.9.15.2673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
94 Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, Kamaya A, Sirlin C. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System. Radiol Clin North Am 2017;55:1197-209. [PMID: 28991560 DOI: 10.1016/j.rcl.2017.06.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
95 El-Senduny FF, Zidane MM, Youssef MM, Badria FA. An Approach to Treatment of Liver Cancer by Novel Glycyrrhizin Derivative. Anticancer Agents Med Chem 2019;19:1863-73. [PMID: 30973113 DOI: 10.2174/1871520619666190411114718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29.epidemiology] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007;45:1169-1179. [PMID: 17635075 DOI: 10.1515/cclm.2007.262] [Cited by in Crossref: 58] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
98 Lee TK, Castilho A, Ma S, Ng IO. Liver cancer stem cells: implications for a new therapeutic target. Liver Int. 2009;29:955-965. [PMID: 19490415 DOI: 10.1111/j.1478-3231.2009.02040.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
99 Eaton D, Beima K, Bammler T, Riley R, Voss K. Hepatotoxic Mycotoxins. Comprehensive Toxicology. Elsevier; 2010. pp. 527-69. [DOI: 10.1016/b978-0-08-046884-6.01023-x] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
100 Radunz S, Treckmann J, Baba HA, Best J, Müller S, Theysohn JM, Paul A, Benkö T. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. Ann Transplant 2017;22:215-21. [PMID: 28408731 DOI: 10.12659/aot.902595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
101 Domfeh SA, Narkwa PW, Quaye O, Kusi KA, Awandare GA, Ansah C, Salam A, Mutocheluh M. Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling. BMC Complement Med Ther 2021;21:161. [PMID: 34078370 DOI: 10.1186/s12906-021-03326-x] [Reference Citation Analysis]
102 Tsedensodnom O, Koga H, Rosenberg SA, Nambotin SB, Carroll JJ, Wands JR, Kim M. Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. Exp Cell Res. 2011;317:920-931. [PMID: 21256126 DOI: 10.1016/j.yexcr.2011.01.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
103 Carta A, Briguglio I, Piras S, Corona P, Boatto G, Nieddu M, Giunchedi P, Marongiu ME, Giliberti G, Iuliano F, Blois S, Ibba C, Busonera B, La Colla P. Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. Bioorganic & Medicinal Chemistry 2011;19:7070-84. [DOI: 10.1016/j.bmc.2011.10.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
104 Scaloni A, Codarin E, Di Maso V, Arena S, Renzone G, Tiribelli C, Quadrifoglio F, Tell G. Modern strategies to identify new molecular targets for the treatment of liver diseases: The promising role of Proteomics and Redox Proteomics investigations. Prot Clin Appl 2009;3:242-62. [DOI: 10.1002/prca.200800169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
105 Kim LH, Nguyen VG, Trinh HN, Li J, Zhang JQ, Nguyen MH. Low Treatment Rates in Patients Meeting Guideline Criteria in Diverse Practice Settings. Dig Dis Sci 2014;59:2091-9. [DOI: 10.1007/s10620-014-3283-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
106 Shen G, Jia H, Tai Q, Li Y, Chen D. miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis. 2013;34:211-219. [PMID: 23087084 DOI: 10.1093/carcin/bgs320] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
107 Kleuser B. Divergent Role of Sphingosine 1-Phosphate in Liver Health and Disease. Int J Mol Sci. 2018;19. [PMID: 29510489 DOI: 10.3390/ijms19030722] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
108 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
109 Chen XZ, Cao ZY, Zhang YQ, Li JN, Liao LM, Du J. Fuzheng Qingjie granules potentiate the anticancer effect of cyclophosphamide by regulating cellular immune function and inducing apoptosis in Hepatoma 22 tumor-bearing mice. Oncol Lett 2017;13:3261-8. [PMID: 28529567 DOI: 10.3892/ol.2017.5849] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
110 Kerdsuknirun J, Vilaichone V, Vilaichone RK. Risk Factors and Prognosis of Spontaneously Ruptured Hepatocellular Carcinoma in Thailand. Asian Pac J Cancer Prev 2018;19:3629-34. [PMID: 30583692 DOI: 10.31557/APJCP.2018.19.12.3629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Aoyama H, Sugita K, Nakamura M, Aoyama A, Salim MT, Okamoto M, Baba M, Hashimoto Y. Fused heterocyclic amido compounds as anti-hepatitis C virus agents. Bioorg Med Chem 2011;19:2675-87. [PMID: 21458278 DOI: 10.1016/j.bmc.2011.03.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
112 Ali SA, Amin DH, Abdelkhalek YI. Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients. Jpn J Radiol 2020;38:472-9. [PMID: 32078123 DOI: 10.1007/s11604-020-00930-8] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
113 Kim SJ, Lee S, Song JD, Kwon Y, Lee K, Koo HC. An InSb-based magnetoresistive biosensor using Fe3O4 nanoparticles. Sensors and Actuators B: Chemical 2018;255:2894-9. [DOI: 10.1016/j.snb.2017.09.108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Schreibman IR, Bejarano P, Martinez EJ, Regev A. Very late recurrence of hepatocellular carcinoma after liver transplantation: case report and literature review. Transplant Proc. 2006;38:3140-3143. [PMID: 17112921 DOI: 10.1016/j.transproceed.2006.08.095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
115 Matos JM, Witzmann FA, Cummings OW, Schmidt CM. A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res 2009;155:237-43. [PMID: 19535095 DOI: 10.1016/j.jss.2008.06.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
116 Makvandi M, Soleimani Jelodar R, Samarbafzadeh A, Neisi N, Sharifi Z, Gholampour A, Masjedizadeh A, Shayesteh A. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran. Asian Pac J Cancer Prev 2018;19:2125-9. [PMID: 30139211 DOI: 10.22034/APJCP.2018.19.8.2125] [Reference Citation Analysis]
117 Peters MG. Managing hepatitis B coinfection in HIV-infected patients. Curr HIV/AIDS Rep 2005;2:122-6. [DOI: 10.1007/s11904-005-0004-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
118 Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 4.7] [Reference Citation Analysis]
119 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, Tiribelli C. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.dimaso] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
120 Gallotti A, D’Onofrio M, Ruzzenente A, Martone E, De Robertis R, Guglielmi A, Pozzi Mucelli R. Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma. Radiol Med. 2009;114:1094-1105. [PMID: 19756947 DOI: 10.1007/s11547-009-0436-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
121 Park JW, Kwak KM, Kim SE, Jang MK, Kim DJ, Lee MS, Kim HS, Park CK. Differentiation of acute and chronic hepatitis B in IgM anti-HBc positive patients. World J Gastroenterol 2015; 21(13): 3953-3959 [PMID: 25852281 DOI: 10.3748/wjg.v21.i13.3953] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
122 Wang L, Li H, Zhang Y, Santella RM, Weinstein IB. HINT1 inhibits beta-catenin/TCF4, USF2 and NFkappaB activity in human hepatoma cells. Int J Cancer 2009;124:1526-34. [PMID: 19089909 DOI: 10.1002/ijc.24072] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
123 Li X, Wang H, Li T, Wang L, Wu X, Liu J, Xu Y, Wei W. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer 2020;44:100516. [PMID: 31836136 DOI: 10.1016/j.currproblcancer.2019.100516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
124 Font-Burgada J, Sun B, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 2016;23:48-62. [PMID: 26771116 DOI: 10.1016/j.cmet.2015.12.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 171] [Article Influence: 32.8] [Reference Citation Analysis]
125 Kido T, Lo RC, Li Y, Lee J, Tabatabai ZL, Ng IO, Lau YF. The potential contributions of a Y-located protooncogene and its X homologue in sexual dimorphisms in hepatocellular carcinoma. Hum Pathol 2014;45:1847-58. [PMID: 25017435 DOI: 10.1016/j.humpath.2014.05.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
126 Kastl L, Sauer SW, Ruppert T, Beissbarth T, Becker MS, Süss D, Krammer PH, Gülow K. TNF-α mediates mitochondrial uncoupling and enhances ROS-dependent cell migration via NF-κB activation in liver cells. FEBS Lett. 2014;588:175-183. [PMID: 24316229 DOI: 10.1016/j.febslet.2013.11.033] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 8.7] [Reference Citation Analysis]
127 Park EK, Kim HJ, Kim CY, Hur YH, Koh YS, Kim JC, Kim HJ, Kim JW, Cho CK. A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Ann Surg Treat Res 2014;87:72-80. [PMID: 25114886 DOI: 10.4174/astr.2014.87.2.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
128 Lam YF, Yuen MF, Seto WK, Lai CL. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep. 2011;10:235-243. [PMID: 22131901 DOI: 10.1007/s11901-011-0109-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
129 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Dong D, Zou Y, Zhang P, Wu Z. Systematic analyses and comprehensive field synopsis of genetic association studies in hepatocellular carcinoma. Oncotarget 2016;7:45757-63. [PMID: 27304192 DOI: 10.18632/oncotarget.9937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
131 Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Huang W, Song HF, Chen MS, Xia JC. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:535-541. [PMID: 17917742 DOI: 10.1007/s00432-007-0316-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
132 Zhang W, Zhangyuan G, Wang F, Jin K, Shen H, Zhang L, Yuan X, Wang J, Zhang H, Yu W, Huang R, Xu X, Yin Y, Zhong G, Lin A, Sun B. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity 2021;54:1168-1185.e8. [PMID: 34038747 DOI: 10.1016/j.immuni.2021.04.027] [Reference Citation Analysis]
133 Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S206-14. [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5] [Cited by in Crossref: 347] [Cited by in F6Publishing: 196] [Article Influence: 28.9] [Reference Citation Analysis]
134 Pazgan-Simon M, Serafinska S, Janocha-Litwin J, Simon K, Zuwala-Jagiello J. Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature. Case Rep Oncol Med 2015;2015:878763. [PMID: 25922775 DOI: 10.1155/2015/878763] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 van den Bos IC, Hussain SM, de Man RA, Zondervan PE, Ijzermans JN, Krestin GP. Primary hepatocellular lesions: imaging findings on state-of-the-art magnetic resonance imaging, with pathologic correlation. Curr Probl Diagn Radiol. 2008;37:104-114. [PMID: 18436110 DOI: 10.1067/j.cpradiol.2007.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
136 Kulanthaivel L, Srinivasan P, Shanmugam V, Periyasamy BM. Therapeutic efficacy of kaempferol against AFB1 induced experimental hepatocarcinogenesis with reference to lipid peroxidation, antioxidants and biotransformation enzymes. Biomedicine & Preventive Nutrition 2012;2:252-9. [DOI: 10.1016/j.bionut.2012.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
137 Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25:3069-3075. [PMID: 17634485 DOI: 10.1200/jco.2006.08.4046] [Cited by in Crossref: 172] [Cited by in F6Publishing: 68] [Article Influence: 11.5] [Reference Citation Analysis]
138 Stearns DM. Evaluation of chromium(III) genotoxicity with cell culture and in vitro assays. The Nutritional Biochemistry of Chromium (III). Elsevier; 2007. pp. 209-24. [DOI: 10.1016/b978-044453071-4/50011-4] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
139 Roushan MR, Bijani A, Ramzaninejad S, Roushan MH, Amiri MJ, Baiani M. HBeAg seroconversion in children infected during early childhood with hepatitis B virus. J Clin Virol. 2012;55:30-33. [PMID: 22727680 DOI: 10.1016/j.jcv.2012.05.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
140 Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol 2013;59:1107-17. [PMID: 23835194 DOI: 10.1016/j.jhep.2013.07.001] [Cited by in Crossref: 172] [Cited by in F6Publishing: 161] [Article Influence: 19.1] [Reference Citation Analysis]
141 Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D, Ocker M. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011;459:129-39. [DOI: 10.1007/s00428-011-1103-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
142 Mcclune AC, Tong MJ. Is the Search for a Single Comprehensive Staging System for Hepatocellular Carcinoma an Elusive One? Journal of Clinical Gastroenterology 2009;43:697-8. [DOI: 10.1097/mcg.0b013e3181acec0c] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
143 Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95. [PMID: 19669256 DOI: 10.1007/s12072-008-9049-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
144 Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12022-12041 [PMID: 26576089 DOI: 10.3748/wjg.v21.i42.12022] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
145 Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
146 Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538. [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013] [Cited by in Crossref: 1610] [Cited by in F6Publishing: 1598] [Article Influence: 100.6] [Reference Citation Analysis]
147 Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis 2016;5:e273. [PMID: 27918551 DOI: 10.1038/oncsis.2016.77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
148 Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75. [PMID: 29329568 DOI: 10.1186/s12885-017-3921-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
149 Huang LL, Zhang Y, Zhang JX, He LJ, Lai YR, Liao YJ, Tian XP, Deng HX, Liang YJ, Kung HF, Xie D, Zhu SL. Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma. Tumour Biol 2015;36:4405-15. [PMID: 25596704 DOI: 10.1007/s13277-015-3080-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
150 Chen X, Wang H, Xie W, Liang R, Wei Z, Zhi L, Zhang X, Hao B, Zhong S, Zhou G, Zhang L, Gao X, Zhu Y, He F. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenet Genomics 2006;16:219-27. [PMID: 16495781 DOI: 10.1097/01.fpc.0000194424.20393.c6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
151 Söderberg-Nauclér C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259:219-246. [PMID: 16476101 DOI: 10.1111/j.1365-2796.2006.01618.x] [Cited by in Crossref: 224] [Cited by in F6Publishing: 216] [Article Influence: 14.0] [Reference Citation Analysis]
152 Wimmer T, Steiner J, Talakic E, Stauber R, Quehenberger F, Portugaller RH, Schoellnast H. Computed Tomography Perfusion Following Transarterial Chemoembolization of Hepatocellular Carcinoma: A Feasibility Study in the Early Period. J Comput Assist Tomogr 2017;41:708-12. [PMID: 28296685 DOI: 10.1097/RCT.0000000000000592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
153 Quagliata L, Andreozzi M, Kovac M, Tornillo L, Makowska Z, Moretti F, Heim MH, Heinimann K, Piscuoglio S, Terracciano LM. SH2D4A is frequently downregulated in hepatocellular carcinoma and cirrhotic nodules. European Journal of Cancer 2014;50:731-8. [DOI: 10.1016/j.ejca.2013.11.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
154 Granado-serrano AB, Martín MA, Bravo L, Goya L, Ramos S. Quercetin Induces Apoptosis via Caspase Activation, Regulation of Bcl-2, and Inhibition of PI-3-Kinase/Akt and ERK Pathways in a Human Hepatoma Cell Line (HepG2). The Journal of Nutrition 2006;136:2715-21. [DOI: 10.1093/jn/136.11.2715] [Cited by in Crossref: 226] [Cited by in F6Publishing: 207] [Article Influence: 14.1] [Reference Citation Analysis]
155 Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1-17. [PMID: 25444466 DOI: 10.1016/j.soc.2014.09.001] [Cited by in Crossref: 168] [Cited by in F6Publishing: 164] [Article Influence: 21.0] [Reference Citation Analysis]
156 Kälsch J, Padden J, Bertram S, Pott LL, Reis H, Westerwick D, Schaefer CM, Sowa JP, Möllmann D, Fingas C, Dechȇne A, Sitek B, Eisenacher M, Canbay A, Ahrens M, Baba HA. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels. Virchows Arch 2017;470:537-43. [PMID: 28357490 DOI: 10.1007/s00428-017-2114-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
157 Liu Y, Liu A, Xu Z, Yu W, Wang H, Li C, Lin J. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis 2011;16:502-10. [PMID: 21311975 DOI: 10.1007/s10495-011-0578-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
158 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 386] [Article Influence: 34.9] [Reference Citation Analysis]
159 Cereser L, Furlan A, Bagatto D, Girometti R, Como G, Avellini C, Orsaria M, Zuiani C, Bazzocchi M. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr 2010;34:706-11. [PMID: 20861773 DOI: 10.1097/RCT.0b013e3181e1a88e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
160 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
161 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13:631-647. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 6.7] [Reference Citation Analysis]
162 Petsaris O, Vallet S, Le Guillou-Guillemette H, Veillon P, Gouriou S, Barbier G, Nousbaum JB, Saliou P, NKontchou G, Trinchet JC, Lunel-Fabiani F, Payan C. Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence. J Clin Virol 2016;74:19-25. [PMID: 26655076 DOI: 10.1016/j.jcv.2015.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
163 Wang T, Hu HS, Feng YX, Shi J, Li N, Guo WX, Xue J, Xie D, Liu SR, Wu MC, Cheng SQ. Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer 2010;102:1618-26. [PMID: 20461085 DOI: 10.1038/sj.bjc.6605689] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
164 Kossakowski J, Pakosinska-Parys M, Struga M, Dybala I, Koziol AE, La Colla P, Marongiu LE, Ibba C, Collu D, Loddo R. Synthesis and evaluation of in vitro biological activity of 4-substituted arylpiperazine derivatives of 1,7,8,9-tetrachloro-10,10-dimethoxy-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione. Molecules 2009;14:5189-202. [PMID: 20032885 DOI: 10.3390/molecules14125189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
165 Zerbini A, Pilli M, Ferrari C, Missale G. Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis 2006;38:221-5. [PMID: 16461021 DOI: 10.1016/j.dld.2005.12.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
166 Khattab MA, Eslam M, Mousa YI, Ela-adawy N, Fathy S, Shatat M, Abd-aalhalim H, Kamal A, Sharawe MA. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Annals of Hepatology 2012;11:487-94. [DOI: 10.1016/s1665-2681(19)31462-0] [Cited by in Crossref: 32] [Article Influence: 3.2] [Reference Citation Analysis]
167 Jiang W, Wang Z, Li X, Fan X, Duan Y. High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res. 2012;18:293-298. [PMID: 21953322 DOI: 10.1007/s12253-011-9442-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
168 Murakami Y, Kubo S, Tamori A, Itami S, Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T, Taguchi YH. Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Sci Rep 2015;5:16294. [PMID: 26538415 DOI: 10.1038/srep16294] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 9.4] [Reference Citation Analysis]
169 Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA; Brazilian HCC Study Group. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo). 2010;65:1285-1290. [PMID: 21340216 DOI: 10.1590/s1807-59322010001200010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
170 Dugan CM, Fullerton AM, Roth RA, Ganey PE. Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxicol Sci 2011;120:507-18. [PMID: 21245496 DOI: 10.1093/toxsci/kfr005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
171 Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, Liu TZ, Liu JJ, Liu DZ, Ho YS, Wu CH, Chang YJ. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells. Ann Surg Oncol 2012;19:336-43. [PMID: 21516372 DOI: 10.1245/s10434-011-1692-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
172 Lai MW, Huang SF, Lin SM, Chen TC, Lin CY, Yeh CN, Yeh TS, Chen MF, Yeh CT. Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol Res 2009;39:164-76. [PMID: 19208037 DOI: 10.1111/j.1872-034X.2008.00413.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
173 Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Syst Rev 2014;3:21. [PMID: 24602249 DOI: 10.1186/2046-4053-3-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
174 Lu Q, Ling W, Lu C, Li J, Ma L, Quan J, He D, Liu J, Yang J, Wen T, Wu H, Zhu H, Luo Y. Hepatocellular carcinoma: stiffness value and ratio to discriminate malignant from benign focal liver lesions. Radiology 2015;275:880-8. [PMID: 25636031 DOI: 10.1148/radiol.14131164] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
175 Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019;54:746-52. [DOI: 10.1080/00365521.2019.1627580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol. 2014;11:402-409. [PMID: 24686270 DOI: 10.1038/nrgastro.2014.30] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
177 El-Borai MA, Rizk HF, Beltagy DM, El-Deeb IY. Microwave-assisted synthesis of some new pyrazolopyridines and their antioxidant, antitumor and antimicrobial activities. Eur J Med Chem 2013;66:415-22. [PMID: 23831694 DOI: 10.1016/j.ejmech.2013.04.043] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
178 Wang D, Huo R, Cui C, Gao Q, Zong J, Wang Y, Sun Y, Hou R. Anticancer activity and mechanism of total saponins from the residual seed cake of Camellia oleifera Abel. in hepatoma-22 tumor-bearing mice. Food Funct 2019;10:2480-90. [DOI: 10.1039/c9fo00069k] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: A review of literature. World J Gastroenterol 2014; 20(15): 4141-4150 [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
180 Deng Y, Li M, Wang J, Xie L, Li T, He Y, Lu Q, Li R, Tan A, Qin X. Susceptibility to hepatocellular carcinoma in the Chinese population--associations with interleukin-6 receptor polymorphism. Tumour Biol. 2014;35:6383-6388. [PMID: 24668548 DOI: 10.1007/s13277-014-1863-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
181 Filho RM, Carmo RF, Catsman C, Souza C, Silva A, Moura P, Tenorio AL, Vasconcelos LR, Cavalcanti Mdo S, Pereira LM. High frequency of variant alleles of the mannose-binding lectin 2 (MBL2) gene are associated with patients infected by hepatitis B virus. Viral Immunol 2010;23:449-53. [PMID: 20712490 DOI: 10.1089/vim.2009.0105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
182 Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009;51:1030-1036. [PMID: 19864035 DOI: 10.1016/j.jhep.2009.09.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
183 Chen E, Song X, Wang Y, Zhou T, Bai L, Liu L, Liu C, Cheng X, Tang H. Construction of a highly-active, liver-specific transcriptional regulatory element through combination of the albumin promoter and α-fetoprotein enhancer. Plasmid 2011;65:125-31. [DOI: 10.1016/j.plasmid.2010.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
184 Guo Y, Zhao J, Bi J, Wu Q, Wang X, Lai Q. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol 2012;5:37. [PMID: 22760167 DOI: 10.1186/1756-8722-5-37] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
185 Tian X, Li J, Ma ZM, Zhao C, Wan DF, Wen YM. Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1. J Exp Clin Cancer Res. 2009;28:58. [PMID: 19402906 DOI: 10.1186/1756-9966-28-58] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
186 Cantarini MC, de la Monte SM, Pang M, Tong M, D’Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44:446-457. [PMID: 16871543 DOI: 10.1002/hep.21272] [Cited by in Crossref: 95] [Cited by in F6Publishing: 107] [Article Influence: 5.9] [Reference Citation Analysis]
187 Jin J, You H, Yu B, Deng Y, Tang N, Yao G, Shu H, Yang S, Qin W. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun. 2009;379:86-91. [PMID: 19100240 DOI: 10.1016/j.bbrc.2008.12.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
188 Zhu J, Yu K, de Mello RA. Hepatocellular Carcinoma. In: de Mello RA, Tavares Á, Mountzios G, editors. International Manual of Oncology Practice. Cham: Springer International Publishing; 2015. pp. 327-42. [DOI: 10.1007/978-3-319-21683-6_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Yang N, Feng J, Zhou T, Li Z, Chen Z, Ming K, Liang G, Lei XX, Xu BL. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients. J Med Virol 2018;90:1240-5. [PMID: 29603789 DOI: 10.1002/jmv.25080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
190 Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol 2013; 5(9): 186-194 [PMID: 24069511 DOI: 10.4251/wjgo.v5.i9.186] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
191 Briguglio I, Piras S, Corona P, Carta A. Inhibition of RNA Helicases of ssRNA(+) Virus Belonging to Flaviviridae, Coronaviridae and Picornaviridae Families. Int J Med Chem 2011;2011:213135. [PMID: 27516903 DOI: 10.1155/2011/213135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
192 Ezzikouri S, El Feydi AE, Chafik A, Afifi R, El Kihal L, Benazzouz M, Hassar M, Pineau P, Benjelloun S. Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients. Mutat Res 2008;649:1-6. [PMID: 18023606 DOI: 10.1016/j.mrgentox.2007.05.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
193 Rabelo-Gonçalves EM, Roesler BM, Zeitune JM. Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. World J Hepatol 2015; 7(30): 2968-2979 [PMID: 26730276 DOI: 10.4254/wjh.v7.i30.2968] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
194 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
195 Uranbileg B, Ikeda H, Kurano M, Enooku K, Sato M, Saigusa D, Aoki J, Ishizawa T, Hasegawa K, Kokudo N, Yatomi Y. Increased mRNA Levels of Sphingosine Kinases and S1P Lyase and Reduced Levels of S1P Were Observed in Hepatocellular Carcinoma in Association with Poorer Differentiation and Earlier Recurrence. PLoS One 2016;11:e0149462. [PMID: 26886371 DOI: 10.1371/journal.pone.0149462] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
196 Daskalow K, Pfander D, Weichert W, Rohwer N, Thelen A, Neuhaus P, Jonas S, Wiedenmann B, Benckert C, Cramer T. Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 2009;132:21-31. [PMID: 19350262 DOI: 10.1007/s00418-009-0590-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
197 Wang H, Chen L, Zhou T, Zhang Z, Zeng C. Nicotine Promotes WRL68 Cells Proliferation Due to the Mutant p53 Gain-of-Function by Activating CDK6-p53-RS-PIN1-STAT1 Signaling Pathway. Chem Res Toxicol 2020;33:2361-73. [PMID: 32820905 DOI: 10.1021/acs.chemrestox.0c00119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
198 Yang H, Zhai G, Ji X, Su J, Lin M. Reduced expression of argininosuccinate lyase is closely associated with postresectional survival in hepatocellular carcinoma: an immunohistochemistry study of 61 cases. Appl Immunohistochem Mol Morphol 2012;20:602-6. [PMID: 22531684 DOI: 10.1097/PAI.0b013e318250c814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Kuo A, Gish R. Chronic Hepatitis B Infection. Clinics in Liver Disease 2012;16:347-69. [DOI: 10.1016/j.cld.2012.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
200 Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int 2016;36:317-24. [DOI: 10.1111/liv.13031] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 16.1] [Reference Citation Analysis]
201 Mohammadizad H, Shahbazi M, Hasanjani Roushan MR, Soltanzadeh-Yamchi M, Mohammadnia-Afrouzi M. TIM-3 as a marker of exhaustion in CD8+ T cells of active chronic hepatitis B patients. Microb Pathog 2019;128:323-8. [PMID: 30660734 DOI: 10.1016/j.micpath.2019.01.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
202 García-Fulgueiras A, García-Pina R, Morant C, García-Ortuzar V, Génova R, Alvarez E. Hepatitis C and hepatitis B-related mortality in Spain. Eur J Gastroenterol Hepatol. 2009;21:895-901. [PMID: 19357523 DOI: 10.1097/meg.0b013e328313139d] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
203 Funk E, Kottilil S, Gilliam B, Talwani R. Tickling the TLR7 to cure viral hepatitis. J Transl Med 2014;12:129. [PMID: 24884741 DOI: 10.1186/1479-5876-12-129] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
204 de la Torre AN, Contractor S, Castaneda I, Cathcart CS, Razdan D, Klyde D, Kisza P, Gonzales SF, Salazar AM. A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. J Hepatocell Carcinoma 2017;4:111-21. [PMID: 28848723 DOI: 10.2147/JHC.S136652] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
205 Wu X, Xin Z, Zhang W, Wu J, Chen K, Wang H, Zhu X, Pan L, Li Z, Li H, Liu Y. Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity: VEGFA promoter polymorphisms and HCC. Int J Cancer 2013;133:1085-93. [DOI: 10.1002/ijc.28109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
206 Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer. 2007;121:1028-1035. [PMID: 17443492 DOI: 10.1002/ijc.22750] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
207 Endo M, Yasui K, Zen Y, Gen Y, Zen K, Tsuji K, Dohi O, Mitsuyoshi H, Tanaka S, Taniwaki M, Nakanuma Y, Arii S, Yoshikawa T. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma. Liver Int 2013;33:105-17. [PMID: 23088494 DOI: 10.1111/liv.12005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
208 Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 2011;49:1311-1316. [PMID: 21663469 DOI: 10.1515/cclm.2011.640] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
209 Yu YL, Su KJ, Hsieh YH, Lee HL, Chen TY, Hsiao PC, Yang SF. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma. PLoS One 2013;8:e74870. [PMID: 24040354 DOI: 10.1371/journal.pone.0074870] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
210 Zhang LS, Yuan F, Guan X, Li J, Liu XL, Sun J, Liu B, Ma W, Deng FM. Association of Genetic Polymorphisms in HSD17B1, HSD17B2 and SHBG Genes with Hepatocellular Carcinoma Risk. Pathol Oncol Res 2014;20:661-6. [DOI: 10.1007/s12253-014-9746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
211 de Carvalho TF, de Paula Martins Pereira M, Pessanha AT, Tinoco HP, Paixão TA, Santos RL. Hepatocellular carcinoma in two captive golden-headed lion tamarins (Leontopithecus chrysomelas). J Med Primatol 2018;47:110-3. [PMID: 29171026 DOI: 10.1111/jmp.12324] [Reference Citation Analysis]
212 Schiller JT, Lowy DR. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010;64:23-41. [PMID: 20420520 DOI: 10.1146/annurev.micro.112408.134019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
213 Zhang P, Zhang N, Korba BE, Hosmane RS. Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system. Bioorg Med Chem Lett 2005;15:5397-401. [PMID: 16213713 DOI: 10.1016/j.bmcl.2005.09.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
214 Guo Y, Bai M, Lin L, Huang J, An Y, Liang L, Liu Y, Huang W. LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2. Biomedicine & Pharmacotherapy 2019;118:109272. [DOI: 10.1016/j.biopha.2019.109272] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
215 Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, Yeh YH, Su SC, Chen YC, Chen MK. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1808-1815. [PMID: 20119675 DOI: 10.1245/s10434-009-0904-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
216 Piciocchi M, Cardin R, Vitale A, Vanin V, Giacomin A, Pozzan C, Maddalo G, Cillo U, Guido M, Farinati F. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatol Int. 2013;7:1050-1057. [PMID: 26202034 DOI: 10.1007/s12072-013-9481-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
217 Tsuji K, Yasui K, Gen Y, Endo M, Dohi O, Zen K, Mitsuyoshi H, Minami M, Itoh Y, Taniwaki M. PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet. 2010;198:118-125. [PMID: 20362226 DOI: 10.1016/j.cancergencyto.2010.01.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
218 Sekar TV, Mohanram RK, Foygel K, Paulmurugan R. Therapeutic evaluation of microRNAs by molecular imaging. Theranostics 2013;3:964-85. [PMID: 24396507 DOI: 10.7150/thno.4928] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
219 Lorenz O, Parzefall W, Kainzbauer E, Wimmer H, Grasl-Kraupp B, Gerner C, Schulte-Hermann R. Proteomics reveals acute pro-inflammatory and protective responses in rat Kupffer cells and hepatocytes after chemical initiation of liver cancer and after LPS and IL-6. Proteomics Clin Appl 2009;3:947-67. [PMID: 21136998 DOI: 10.1002/prca.200800173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
220 Farrag NS, Amin AM. Preliminary evaluation of the radiotherapeutic efficacy of 131I-atorvastatin in rats with hepatocellular carcinoma. NUCL SCI TECH 2020;31. [DOI: 10.1007/s41365-020-00819-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Tsai HT, Yang SF, Chen DR, Chan SE. CCL5-28, CCL5-403, and CCR5 genetic polymorphisms and their synergic effect with alcohol and tobacco consumptions increase susceptibility to hepatocellular carcinoma. Med Oncol 2012;29:2771-9. [PMID: 22374185 DOI: 10.1007/s12032-012-0189-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
222 Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, Qin LX, Turlin B, Tang ZY, Mazzaferro V. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res. 2008;653:6-13. [PMID: 18467159 DOI: 10.1016/j.mrgentox.2008.01.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
223 Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008;99:143-150. [PMID: 18577996 DOI: 10.1038/sj.bjc.6604422] [Cited by in Crossref: 136] [Cited by in F6Publishing: 134] [Article Influence: 9.7] [Reference Citation Analysis]
224 Park HS, Jang KY, Kim YK, Cho BH, Moon WS. Hepatocellular carcinoma with massive lymphoid infiltration: A regressing phenomenon? Pathology - Research and Practice 2009;205:648-52. [DOI: 10.1016/j.prp.2009.01.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
225 Shin E, Kim S, Jeong H, Jang J, Lee K. Nuclear expression of S-phase kinase-associated protein 2 predicts poor prognosis of hepatocellular carcinoma: SKP2 PREDICTS PROGNOSIS OF HEPATOCELLULAR CARCINOMA. APMIS 2012;120:349-57. [DOI: 10.1111/j.1600-0463.2011.02838.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
226 Abu El Makarem MA, Abdel-aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Annals of Hepatology 2011;10:296-305. [DOI: 10.1016/s1665-2681(19)31541-8] [Cited by in Crossref: 40] [Article Influence: 3.6] [Reference Citation Analysis]
227 Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegn㙠L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; FOR THE ITALIAN LIVER CANCER (ITA.LI.CA.) GROUP. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2010;31:493-501. [DOI: 10.1111/j.1365-2036.2009.04198.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
228 Polireddy K, Chavan H, Abdulkarim BA, Krishnamurthy P. Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol 2011;5:410-25. [PMID: 21849266 DOI: 10.1016/j.molonc.2011.07.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
229 Wang B, Hsu CJ, Chou CH, Lee HL, Chiang WL, Su CM, Tsai HC, Yang SF, Tang CH. Variations in the AURKA Gene: Biomarkers for the Development and Progression of Hepatocellular Carcinoma. Int J Med Sci 2018;15:170-5. [PMID: 29333101 DOI: 10.7150/ijms.22513] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
230 Williams DE, Orner G, Willard KD, Tilton S, Hendricks JD, Pereira C, Benninghoff AD, Bailey GS. Rainbow trout (Oncorhynchus mykiss) and ultra-low dose cancer studies. Comp Biochem Physiol C Toxicol Pharmacol 2009;149:175-81. [PMID: 19135172 DOI: 10.1016/j.cbpc.2008.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
231 Liang L, Guan J, Zeng Y, Wang J, Li X, Zhang X, Ding Y. Down-regulation of formin-like 2 predicts poor prognosis in hepatocellular carcinoma. Hum Pathol 2011;42:1603-12. [PMID: 21496865 DOI: 10.1016/j.humpath.2010.08.025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
232 Tan GS, Lim KH, Tan HT, Khoo ML, Tan SH, Toh HC, Ching Ming Chung M. Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients. J Proteome Res. 2014;13:4833-4846. [PMID: 24946162 DOI: 10.1021/pr500229n] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
233 Ahmad J, Wahab R, Siddiqui MA, Musarrat J, Al-Khedhairy AA. Zinc oxide quantum dots: a potential candidate to detain liver cancer cells. Bioprocess Biosyst Eng 2015;38:155-63. [PMID: 25073692 DOI: 10.1007/s00449-014-1254-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
234 Sherman M, Llovet JM. Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma. J Natl Cancer Inst 2011;103:1642-3. [PMID: 22021668 DOI: 10.1093/jnci/djr430] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
235 Piros L, Fehérvári I, Görög D, Nemes B, Szabó J, Gerlei Z, Végső G, Kóbori L, Máthé Z. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest. Transplantation Proceedings 2015;47:2201-6. [DOI: 10.1016/j.transproceed.2015.07.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
236 Wang X, Yang X, Chen F, Wu S, Song Z, Fei J. Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research. Can J Gastroenterol Hepatol 2021;2021:8864655. [PMID: 33505945 DOI: 10.1155/2021/8864655] [Reference Citation Analysis]
237 Hou SC, Xiao MB, Ni RZ, Ni WK, Jiang F, Li XY, Lu CH, Chen BY. Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma. Oncol Lett 2013;6:1152-8. [PMID: 24137480 DOI: 10.3892/ol.2013.1522] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
238 Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Aillères N, Azria D. [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother 2019;23:636-50. [PMID: 31444078 DOI: 10.1016/j.canrad.2019.07.159] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
239 Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Higuchi T, Miyakubo M, Ishikita T, Nakajima T, Endo K. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med. 2008;22:83-86. [PMID: 18250992 DOI: 10.1007/s12149-007-0076-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
240 Čizmarević U, Hanžič N, Polanec B, Rupreht M. Unusual Presentation of Hepatocellular Carcinoma and Rare Metastasis to the Masticatory Space. Cureus 2019;11:e5802. [PMID: 31728249 DOI: 10.7759/cureus.5802] [Reference Citation Analysis]
241 Wang S, Kong X, Yang C, Zhang J, Li C, Ouyang J, Wang Z. Extracorporeal high intensity focused ultrasound treatment for a child with recurrence of hepatocellular carcinoma. European Journal of Radiology Extra 2010;75:e101-3. [DOI: 10.1016/j.ejrex.2010.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
242 Saad-Hussein A, Taha MM, Beshir S, Shahy EM, Shaheen W, Elhamshary M. Carcinogenic effects of aflatoxin B1 among wheat handlers. Int J Occup Environ Health. 2014;20:215-219. [PMID: 25000109 DOI: 10.1179/2049396714y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Cameron AM. Screening for Viral Hepatitis and Hepatocellular Cancer. Surg Clin North Am 2015;95:1013-21. [PMID: 26315520 DOI: 10.1016/j.suc.2015.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
244 Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targ Oncol 2017;12:795-803. [DOI: 10.1007/s11523-017-0522-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
245 Rao A, Rao G, Ahmed I. Laparoscopic vs. open liver resection for malignant liver disease. A systematic review. Surgeon. 2012;10:194-201. [PMID: 22818276 DOI: 10.1016/j.surge.2011.06.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
246 Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Poggio PD, Rapaccini G, Nolfo AM, Benvegnù L. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. Liver Int. 2013;33:1420-1427. [PMID: 23758775 DOI: 10.1111/liv.12208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
247 Dugum M, Hanouneh I, Lopez R, Aucejo F, Eghtesad B, Zein N. Hepatocellular Carcinoma in the Setting of Chronic Hepatitis B Virus Infection: Tumor Recurrence and Survival Rates After Liver Transplantation. Transplant Proc. 2015;47:1939-1944. [PMID: 26293077 DOI: 10.1016/j.transproceed.2015.02.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
248 Tanabe K, Kitagawa K, Kojima N, Iijima S. Multifucosylated Alpha-1-acid Glycoprotein as a Novel Marker for Hepatocellular Carcinoma. J Proteome Res. 2016;15:2935-2944. [PMID: 27354006 DOI: 10.1021/acs.jproteome.5b01145] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
249 Carta A, Loriga M, Paglietti G, Ferrone M, Fermeglia M, Pricl S, Sanna T, Ibba C, La Colla P, Loddo R. Design, synthesis, and preliminary in vitro and in silico antiviral activity of [4,7]phenantrolines and 1-oxo-1,4-dihydro-[4,7]phenantrolines against single-stranded positive-sense RNA genome viruses. Bioorganic & Medicinal Chemistry 2007;15:1914-27. [DOI: 10.1016/j.bmc.2007.01.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
250 Rauchfuss F, Scheuerlein H, Götz M, Dittmar Y, Voigt R, Heise M, Settmacher U. [Hepatocellular carcinoma and cholangiocarcinoma]. Chirurg 2010;81:941-52; quiz 953. [PMID: 20827454 DOI: 10.1007/s00104-009-1864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
251 Liu KY, Wang LT, Hsu SH. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E8. [PMID: 29301348 DOI: 10.3390/cancers10010008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
252 Volk ML, Lok AS. Is family history of liver cancer a risk factor for hepatocellular carcinoma? J Hepatol 2009;50:247-8. [PMID: 19070916 DOI: 10.1016/j.jhep.2008.11.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
253 Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008;26:6244-57. [PMID: 18694795 DOI: 10.1016/j.vaccine.2008.07.056] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
254 Sun B, Zheng CS, Feng GS, Wang Y, Xia XW, Kan XF. Radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3255-3263 [DOI: 10.11569/wcjd.v19.i31.3255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
255 Karagozian R, Baker E, Houranieh A, Leavitt D, Baffy G. Risk profile of hepatocellular carcinoma reveals dichotomy among US veterans. J Gastrointest Cancer 2013;44:318-24. [PMID: 23609167 DOI: 10.1007/s12029-013-9499-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
256 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
257 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1543] [Article Influence: 111.7] [Reference Citation Analysis]
258 Wong LL, Ogihara M, Ji J, Tsai N. The changing characteristics of hepatocellular cancer in Hawaii over time. Am J Surg 2015;210:146-52. [PMID: 25510478 DOI: 10.1016/j.amjsurg.2014.06.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
259 Ezzikouri S, El Feydi AE, Afifi R, El Kihal L, Benazzouz M, Hassar M, Marchio A, Pineau P, Benjelloun S. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev. 2009;32:380-385. [PMID: 19233569 DOI: 10.1016/j.cdp.2009.01.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
260 Sun Z, Zhao L, Wang S, Wang H. Knockdown of long non-coding RNA LINC01006 represses the development of hepatocellular carcinoma by modulating the miR-194-5p/CADM1 axis. Ann Hepatol 2021;:100571. [PMID: 34718169 DOI: 10.1016/j.aohep.2021.100571] [Reference Citation Analysis]
261 Ji Z, Meng G, Huang D, Yue X, Wang B. NMFBFS: A NMF-Based Feature Selection Method in Identifying Pivotal Clinical Symptoms of Hepatocellular Carcinoma. Comput Math Methods Med 2015;2015:846942. [PMID: 26579207 DOI: 10.1155/2015/846942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
262 Ma J, Zhang Y, Chen X, Jin Y, Chen D, Wu Y, Cui J, Wang H, Liu J, Li N, Gao F. Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLoS One 2013;8:e67606. [PMID: 23935839 DOI: 10.1371/journal.pone.0067606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
263 Li YY, Sha WH, Zhou YJ, Nie YQ. Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:2148-2154. [PMID: 18031373 DOI: 10.1111/j.1440-1746.2006.04719.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
264 Toro A, Pulvirenti E, Palermo F, Di Carlo I. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol 2012;21:e23-30. [PMID: 22104002 DOI: 10.1016/j.suronc.2011.10.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
265 Giunchedi P, Maestri M, Gavini E, Dionigi P, Rassu G. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. Expert Opin Drug Deliv 2013;10:679-90. [PMID: 23406440 DOI: 10.1517/17425247.2013.770733] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
266 Hong TP, Gow P, Fink M, Dev A, Roberts S, Nicoll A, Lubel J, Kronborg I, Arachchi N, Ryan M, Kemp W, Knight V, Farrugia H, Thursfield V, Desmond P, Thompson AJ, Bell S. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed: Hepatology, Vol. XX, No. X, 2015. Hepatology 2016;63:1205-12. [DOI: 10.1002/hep.28267] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
267 Yue-Meng W, Li YH, Wu HM, Yang J, Xu Y, Yang LH, Yang JH. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis. Clin Exp Med 2017;17:233-41. [PMID: 27094312 DOI: 10.1007/s10238-016-0420-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
268 Wang B, Yeh CB, Lein MY, Su CM, Yang SF, Liu YF, Tang CH. Effects of HMGB1 Polymorphisms on the Susceptibility and Progression of Hepatocellular Carcinoma. Int J Med Sci. 2016;13:304-309. [PMID: 27076788 DOI: 10.7150/ijms.14877] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
269 Uranbileg B, Enooku K, Soroida Y, Ohkawa R, Kudo Y, Nakagawa H, Tateishi R, Yoshida H, Shinzawa S, Moriya K, Ohtomo N, Nishikawa T, Inoue Y, Tomiya T, Kojima S, Matsuura T, Koike K, Yatomi Y, Ikeda H. High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential. Int J Cancer 2014;134:2189-98. [PMID: 24174293 DOI: 10.1002/ijc.28547] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
270 Liu T, Jiang W, Han D, Yu L. DNAJC25 is downregulated in hepatocellular carcinoma and is a novel tumor suppressor gene. Oncol Lett 2012;4:1274-80. [PMID: 23205125 DOI: 10.3892/ol.2012.903] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
271 Nesher N, Haim MB, Pevni D, Kessler A, Paz Y. Ultrasound-Guided, Video-Assisted Transdiaphragmatic Radiofrequency Ablation for Primary Liver Malignancy or Metastatic Nodules. Innovations�(Phila) 2011;6:337-40. [DOI: 10.1097/imi.0b013e3182362738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
272 Tao J, Zhang W, Yue H, Zhu G, Wu W, Gong W, Fang H, He G, Hu X, Zhao H, Liu A. Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018. Sci Rep 2019;9:13948. [PMID: 31558731 DOI: 10.1038/s41598-019-50173-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
273 Vrancken K, Paeshuyse J, Liekens S. Angiogenic activity of hepatitis B and C viruses. Antivir Chem Chemother. 2012;22:159-170. [PMID: 22182803 DOI: 10.3851/imp1987] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
274 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29] [Cited by in Crossref: 642] [Cited by in F6Publishing: 412] [Article Influence: 71.3] [Reference Citation Analysis]
275 Kim HY, Cho HK, Hong SP, Cheong J. Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells. Cancer Lett. 2011;309:176-184. [PMID: 21726936 DOI: 10.1016/j.canlet.2011.05.033] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
276 Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P, Wands JR. Functional interaction between Wnt3 and Frizzled-7 Leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 2008;48:780-791. [PMID: 18313787 DOI: 10.1016/j.jhep.2007.12.020] [Cited by in Crossref: 124] [Cited by in F6Publishing: 123] [Article Influence: 8.9] [Reference Citation Analysis]
277 Hu J, Xu Y, Shen ZZ, Wang Z, Lu Q, Yang GH, Ding ZB, Fan J, Zhou J. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 2009;135:1359-1367. [PMID: 19350273 DOI: 10.1007/s00432-009-0577-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
278 Tonelli M, Boido V, Colla P, Loddo R, Posocco P, Paneni MS, Fermeglia M, Pricl S. Pharmacophore modeling, resistant mutant isolation, docking, and MM-PBSA analysis: Combined experimental/computer-assisted approaches to identify new inhibitors of the bovine viral diarrhea virus (BVDV). Bioorg Med Chem 2010;18:2304-16. [PMID: 20189812 DOI: 10.1016/j.bmc.2010.01.058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
279 Park UJ, Kim YH, Kang KJ, Lim TJ. [Risk factors for early recurrence after surgical resection for hepatocellular carcinoma]. Korean J Hepatol. 2008;14:371-380. [PMID: 18815460 DOI: 10.3350/kjhep.2008.14.3.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
280 Tian XF, Fan XG, Zhang Y, Huang Y, Dai H, Ying RS. Procuration and identification of bacteria in paraffin-embedded liver tissues of hepatocellular carcinoma by laser-assisted microdissection technique. APMIS. 2008;116:10-15. [PMID: 18254774 DOI: 10.1111/j.1600-0463.2008.00739.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
281 Zou SW, Ai KX, Wang ZG, Yuan Z, Yan J, Zheng Q. The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells. Acta Pharmacol Sin 2011;32:354-60. [PMID: 21372827 DOI: 10.1038/aps.2010.223] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
282 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Reference Citation Analysis]
283 Sartori Balbinot R, Facco Muscope AL, Dal Castel M, Sartori Balbinot S, Angelo Balbinot R, Soldera J. Intraparenchymal Hemorrhage due to Brain Metastasis of Hepatocellular Carcinoma. Case Rep Gastroenterol 2017;11:516-25. [PMID: 29033772 DOI: 10.1159/000479221] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
284 Tangkijvanich P, Hourpai N, Rattanatanyong P, Wisedopas N, Mahachai V, Mutirangura A. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta. 2007;379:127-133. [PMID: 17303099 DOI: 10.1016/j.cca.2006.12.029] [Cited by in Crossref: 92] [Cited by in F6Publishing: 86] [Article Influence: 6.1] [Reference Citation Analysis]
285 Yasui K, Takashima H, Miyagawa M, Miyazawa K, Ochiai T, Mukaisho K, Amaike H, Ueda K, Morikawa J, Otsuji E, Yoshikawa T. Selective accumulation of platinum and formation of platinum-DNA adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin. Hepatol Res 2013;43:1093-9. [PMID: 23347452 DOI: 10.1111/hepr.12059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Rashid F, Shah A, Shan G. Long Non-coding RNAs in the Cytoplasm. Genomics Proteomics Bioinformatics 2016;14:73-80. [PMID: 27163185 DOI: 10.1016/j.gpb.2016.03.005] [Cited by in Crossref: 173] [Cited by in F6Publishing: 176] [Article Influence: 28.8] [Reference Citation Analysis]
287 Liew ZH, Goh GB, Hao Y, Chang PE, Tan CK. Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades. Dig Dis Sci 2019;64:585-90. [PMID: 30327962 DOI: 10.1007/s10620-018-5331-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
288 Marugán RB, Garzón SG. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009; 15(4): 423-430 [PMID: 19152446 DOI: 10.3748/wjg.15.423] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
289 Yan L, Jakate S, Reddy V, Gattuso P. Metastatic hepatocellular carcinoma diagnosed by fine needle aspiration: A clinical and cytologic study. Diagn Cytopathol 2018;46:495-500. [PMID: 29493103 DOI: 10.1002/dc.23920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
290 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
291 Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167-1178. [PMID: 24039437 DOI: 10.2147/ott.s36161] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
292 Lionço LC, de Mattos AA, Horbe AF, Costabeber AM, de Mattos ÂZ, Tarasconi DP. Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil. Eur J Gastroenterol Hepatol 2017;29:225-30. [PMID: 27759574 DOI: 10.1097/MEG.0000000000000764] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
293 Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b. Gastroenterology 2008;135:459-67. [DOI: 10.1053/j.gastro.2008.05.031] [Cited by in Crossref: 278] [Cited by in F6Publishing: 246] [Article Influence: 19.9] [Reference Citation Analysis]
294 Kang HJ, Seol HS, Lee SE, Suh YA, Kim J, Jang SJ, Yu E. Guanabenz Acetate Induces Endoplasmic Reticulum Stress-Related Cell Death in Hepatocellular Carcinoma Cells. J Pathol Transl Med 2019;53:94-103. [PMID: 30646673 DOI: 10.4132/jptm.2019.01.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
295 McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol. 2009;4:399-415. [PMID: 18928409 DOI: 10.1146/annurev.pathol.4.110807.092202] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
296 Mason WS, Liu C, Aldrich CE, Litwin S, Yeh MM. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J Virol. 2010;84:8308-8315. [PMID: 20519397 DOI: 10.1128/jvi.00833-10] [Cited by in Crossref: 72] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
297 Brozzetti S, Bini S, Fazzi K, Chiarella LL, Ceccarossi V, De Lucia C, De Toma G. Case-report: Metastases in a low-stage middle-graded HCC in cleared HCV infection, non-cirrhotic liver: Surgical therapy. Int J Surg Case Rep 2018;47:19-21. [PMID: 29704738 DOI: 10.1016/j.ijscr.2018.04.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009;100:1234-1242. [PMID: 19486339 DOI: 10.1111/j.1349-7006.2009.01164.x] [Cited by in Crossref: 209] [Cited by in F6Publishing: 202] [Article Influence: 16.1] [Reference Citation Analysis]
299 Xie HJ, Jung KH, Nam SW. Overexpression of SIRT2 contributes tumor cell growth in hepatocellular carcinomas. Mol Cell Toxicol 2011;7:367-74. [DOI: 10.1007/s13273-011-0046-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
300 Geng M, Cao YC, Chen YJ, Jiang H, Bi LQ, Liu XH. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol 2012; 18(12): 1328-1338 [PMID: 22493546 DOI: 10.3748/wjg.v18.i12.1328] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
301 Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44 Suppl 19:96-101. [PMID: 19148801 DOI: 10.1007/s00535-008-2258-6] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 10.4] [Reference Citation Analysis]
302 Chen CC, Chang CM, Sun CP, Yu CP, Wu PY, Jeng KS, Hu CP, Chen PJ, Wu JC, Shih CH, Gershwin ME, Tao MH. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Ther 2012;19:25-33. [PMID: 21562593 DOI: 10.1038/gt.2011.60] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
303 Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24:70-78. [PMID: 23928932 DOI: 10.1007/s00330-013-2978-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 106] [Article Influence: 12.3] [Reference Citation Analysis]
304 Lehman EM, Soliman AS, Ismail K, Hablas A, Seifeldin IA, Ramadan M, El-Hamzawy H, Shoushtari CS, Wilson ML. Patterns of hepatocellular carcinoma incidence in Egypt from a population-based cancer registry. Hepatol Res 2008;38:465-73. [PMID: 18042228 DOI: 10.1111/j.1872-034X.2007.00299.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
305 Liu J, Li G, Wang X, Wang L, Zhao R, Wang J, Kong Y, Ding J, Li J, Zhang L. Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP. Transl Oncol 2016;9:70-8. [PMID: 26947884 DOI: 10.1016/j.tranon.2016.01.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
306 Yang J, Jin X, Yan Y, Shao Y, Pan Y, Roberts LR, Zhang J, Huang H, Jiang J. Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. Sci Rep 2017;7:43864. [PMID: 28262837 DOI: 10.1038/srep43864] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
307 Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients. BMC Gastroenterol 2017;17:39. [PMID: 28279168 DOI: 10.1186/s12876-017-0596-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
308 Guglielmi A, Ruzzenente A, Valdegamberi A, Pachera S, Campagnaro T, D’Onofrio M, Martone E, Nicoli P, Iacono C. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg. 2008;12:192-198. [PMID: 17999123 DOI: 10.1007/s11605-007-0392-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 109] [Article Influence: 7.4] [Reference Citation Analysis]
309 Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of life in HCC Patients Treated with Transarterial Chemoembolization. HPB Surg. 2016;2016:6120143. [PMID: 27143815 DOI: 10.1155/2016/6120143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
310 Koh C, Liang TJ. Settling the "score" with liver cancer. J Hepatol 2009;50:7-9. [PMID: 19014877 DOI: 10.1016/j.jhep.2008.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
311 Yu DC, Liu J, Chen J, Shao JJ, Shen X, Xia HG, Li CJ, Xue B, Ding YT. GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis. BMC Cancer 2014;14:248. [PMID: 24716791 DOI: 10.1186/1471-2407-14-248] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
312 Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int 2017;11:45-53. [PMID: 27271356 DOI: 10.1007/s12072-016-9743-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
313 Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kiliç M. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2010;16:621-630. [PMID: 20440771 DOI: 10.1002/lt.22028] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
314 Herzig MC, Zavadil JA, Street K, Hildreth K, Drinkwater NR, Reddick T, Herbert DC, Hanes MA, McMahan CA, Reddick RL, Walter CA. DNA Alkylating Agent Protects Against Spontaneous Hepatocellular Carcinoma Regardless of O6-Methylguanine-DNA Methyltransferase Status. Cancer Prev Res (Phila) 2016;9:245-52. [PMID: 26667451 DOI: 10.1158/1940-6207.CAPR-15-0251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
315 Shih YL, Kuo CC, Yan MD, Lin YW, Hsieh CB, Hsieh TY. Quantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinoma. Clin Epigenetics. 2016;8:41. [PMID: 27110298 DOI: 10.1186/s13148-016-0208-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
316 Carter S, Martin Ii RC. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (Oxford) 2009;11:541-50. [PMID: 20495705 DOI: 10.1111/j.1477-2574.2009.00071.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
317 Ohata T, Yokoo H, Kamiyama T, Fukai M, Aiyama T, Hatanaka Y, Hatanaka K, Wakayama K, Orimo T, Kakisaka T, Kobayashi N, Matsuno Y, Taketomi A. Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition. Cancer Med 2017;6:1049-61. [PMID: 28374947 DOI: 10.1002/cam4.1020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
318 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
319 Tataria M, Perryman SV, Sylvester KG. Stem cells: tissue regeneration and cancer. Semin Pediatr Surg 2006;15:284-92. [PMID: 17055959 DOI: 10.1053/j.sempedsurg.2006.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
320 Wang BF, Wang Y, Wang BY, Sun FR, Zhang D, Chen YS. Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil. J Clin Pharm Ther 2015;40:345-8. [PMID: 25721615 DOI: 10.1111/jcpt.12259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
321 Van Thiel DH, Ramadori G. Non-viral causes of hepatocellular carcinoma. J Gastrointest Cancer. 2011;42:191-194. [PMID: 20820946 DOI: 10.1007/s12029-010-9195-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
322 Amougou MA, Noah DN, Moundipa PF, Pineau P, Njouom R. A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. BMC Infect Dis 2016;16:647. [PMID: 27821080 DOI: 10.1186/s12879-016-1992-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
323 Heyns C, Bornman M. Men's Health in Africa: Part 2: Non-communicable diseases, malignancies and socio-economic determinants of health. Journal of Men's Health 2008;5:127-32. [DOI: 10.1016/j.jomh.2007.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
324 Guarino M, Di Costanzo GG, Gallotta A, Tortora R, Paneghetti L, Auriemma F, Tuccillo C, Fassina G, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest 2017;77:448-53. [PMID: 28609160 DOI: 10.1080/00365513.2017.1336569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
325 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.di] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
326 Jiang Q, Huang YQ, Huang ZS. Relationship between Helicobacter hepaticus infection and hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(14): 1959-1965 [DOI: 10.11569/wcjd.v22.i14.1959] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
327 Grassi I, Morigi JJ, Nanni C, Fanti S. FDG and other radiopharmaceuticals in the evaluation of liver lesions. Clin Transl Imaging 2014;2:115-27. [DOI: 10.1007/s40336-014-0059-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
328 Diaz-Mitoma F, Popovic V, Spaans JN. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial. Vaccine 2021;39:3892-9. [PMID: 34116873 DOI: 10.1016/j.vaccine.2021.05.067] [Reference Citation Analysis]
329 Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, Pillai AA, Kim HS. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015;30:1167-1174. [PMID: 25675849 DOI: 10.1111/jgh.12920] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
330 Amr KS, Ezzat WM, Elhosary YA, Hegazy AE, Fahim HH, Kamel RR. The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene. 2016;575:66-70. [PMID: 26302751 DOI: 10.1016/j.gene.2015.08.038] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
331 Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe 2007;28:261-8. [PMID: 17605064 DOI: 10.1007/s00292-007-0890-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
332 Chen CT, Lee HL, Chiou HL, Chou CH, Wang PH, Yang SF, Chou YE. Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development. PLoS One 2018;13:e0198967. [PMID: 29889892 DOI: 10.1371/journal.pone.0198967] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
333 Giacomin A, Sergio A, Vanin V, Gazzola A, Cazzagon N, Farinati F. Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges. Dig Dis 2012;30:284-8. [PMID: 22722553 DOI: 10.1159/000336993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
334 Toniutto P, Fattovich G, Fabris C, Minisini R, Burlone M, Pravadelli C, Peraro L, Falleti E, Caldera F, Bitetto D. Genetic polymorphism at the apolipoprotein E locus affects the outcome of chronic hepatitis B. J Med Virol. 2010;82:224-331. [PMID: 20029801 DOI: 10.1002/jmv.21642] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
335 Djokic M, Cemazar M, Popovic P, Kos B, Dezman R, Bosnjak M, Zakelj MN, Miklavcic D, Potrc S, Stabuc B, Tomazic A, Sersa G, Trotovsek B. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. Eur J Surg Oncol. 2018;44:651-657. [PMID: 29402556 DOI: 10.1016/j.ejso.2018.01.090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
336 Li CL, Yeh KH, Liu WH, Chen CL, Chen DS, Chen PJ, Yeh SH. Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-α in female hepatocellular carcinoma. Int J Cancer. 2015;136:761-770. [PMID: 24975878 DOI: 10.1002/ijc.29052] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
337 Kao CC, Chen MK, Kuo WH, Chen TY, Su SC, Hsieh YH, Liu CL, Chou MC, Tsai HT, Yang SF. Influence of glutathione-S-transferase theta (GSTT1) and micro (GSTM1) gene polymorphisms on the susceptibility of hepatocellular carcinoma in Taiwan. J Surg Oncol 2010;102:301-7. [PMID: 20672314 DOI: 10.1002/jso.21643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
338 Mohamed AA, Omran D, El-Feky S, Darwish H, Kassas A, Farouk A, Ezzat O, Abdo SM, Zahran FE, El-Demery A, Omran MM. Toll-like receptor 7 mRNA is reduced in hepatitis C-based liver cirrhosis and hepatocellular carcinoma, out-performs alpha-fetoprotein levels, and with age and serum aspartate aminotransferase is a new diagnostic index. Br J Biomed Sci 2021;78:18-22. [PMID: 32573389 DOI: 10.1080/09674845.2020.1778842] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
339 Khan R, Siddiqui NN, Ul Haq A, Rahman MA. Introducing differential expression of human heat shock protein 27 in hepatocellular carcinoma: moving toward identification of cancer biomarker. Tumour Biol 2016;37:715-21. [PMID: 26242269 DOI: 10.1007/s13277-015-3858-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
340 Chen C, Iloeje UH, Yang H. Long-Term Outcomes in Hepatitis B: The REVEAL-HBV Study. Clinics in Liver Disease 2007;11:797-816. [DOI: 10.1016/j.cld.2007.08.005] [Cited by in Crossref: 131] [Cited by in F6Publishing: 119] [Article Influence: 8.7] [Reference Citation Analysis]
341 Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7:580-585. [PMID: 19418607 DOI: 10.1016/j.cgh.2009.01.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
342 Jia Z, Zhang H, Li N. Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials. J Gastroenterol Hepatol 2021;36:1769-77. [PMID: 33569810 DOI: 10.1111/jgh.15440] [Reference Citation Analysis]
343 Abdel-Hamid NM, Mohafez OM, Nazmy MH, Farhan A, Thabet K. The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma. Environ Health Prev Med 2015;20:195-203. [PMID: 25726025 DOI: 10.1007/s12199-015-0451-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
344 Vineis P, Xun W. The emerging epidemic of environmental cancers in developing countries. Annals of Oncology 2009;20:205-12. [DOI: 10.1093/annonc/mdn596] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
345 Inagaki Y, Yasui K, Endo M, Nakajima T, Zen K, Tsuji K, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Okanoue T. CREB3L4, INTS3, and SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma. Cancer Genet Cytogenet. 2008;180:30-36. [PMID: 18068530 DOI: 10.1016/j.cancergencyto.2007.09.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
346 Singh R, Sharma J, Goyal PK. Prophylactic Role of Averrhoa carambola (Star Fruit) Extract against Chemically Induced Hepatocellular Carcinoma in Swiss Albino Mice. Adv Pharmacol Sci 2014;2014:158936. [PMID: 24696677 DOI: 10.1155/2014/158936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
347 van den Bos IC, Hussain SM, Terkivatan T, Zondervan PE, de Man RA. Stepwise carcinogenesis of hepatocellular carcinoma in the cirrhotic liver: demonstration on serial MR imaging. J Magn Reson Imaging. 2006;24:1071-1080. [PMID: 17024654 DOI: 10.1002/jmri.20701] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
348 Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 2006;8:1-8. [PMID: 16533420 DOI: 10.1593/neo.05373] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
349 Wang B, Hsu CJ, Lee HL, Chou CH, Su CM, Yang SF, Tang CH. Impact of matrix metalloproteinase-11 gene polymorphisms upon the development and progression of hepatocellular carcinoma. Int J Med Sci 2018;15:653-8. [PMID: 29725257 DOI: 10.7150/ijms.23733] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
350 Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, Yuen MF, Lai CL, Kramvis A, Kew MC, Smuts HE, Netesov SV, Alter HJ, Mizokami M. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006;130:703-714. [PMID: 16530512 DOI: 10.1053/j.gastro.2006.01.032] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 5.3] [Reference Citation Analysis]
351 Tang TC, Man S, Lee CR, Xu P, Kerbel RS. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 2010;12:264-74. [PMID: 20234820 DOI: 10.1593/neo.91872] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
352 Zhang JJ, Chen JT, Hua L, Yao KH, Wang CY. miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway. Biomed Pharmacother 2017;85:472-8. [PMID: 27890434 DOI: 10.1016/j.biopha.2016.11.053] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
353 Keeble S, Quested J, Barker D, Varadarajan A, Shankar AG. Immunization of babies born to HBsAg positive mothers: An audit on the delivery and completeness of follow up in Norfolk and Suffolk, United Kingdom. Hum Vaccin Immunother 2015;11:1153-6. [PMID: 25876072 DOI: 10.1080/21645515.2015.1019977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
354 Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP. Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology. 2008;47:1150-1157. [PMID: 18264998 DOI: 10.1002/hep.22181] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
355 Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 2013;36:449-59. [PMID: 22722717 DOI: 10.1007/s00270-012-0424-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
356 Rac MW, Sheffield JS. Prevention and Management of Viral Hepatitis in Pregnancy. Obstetrics and Gynecology Clinics of North America 2014;41:573-92. [DOI: 10.1016/j.ogc.2014.08.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
357 Venkatesan AM, Gervais DA, Mueller PR. Percutaneous radiofrequency thermal ablation of primary and metastatic hepatic tumors: current concepts and review of the literature. Semin Intervent Radiol. 2006;23:73-84. [PMID: 21326722 DOI: 10.1055/s-2006-939843] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
358 Yoon AJ, Kuo WH, Lin CW, Yang SF. Role of ERCC5 polymorphism in risk of hepatocellular carcinoma. Oncol Lett. 2011;2:911-914. [PMID: 22866149 DOI: 10.3892/ol.2011.325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
359 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
360 Chachá SG, Ferreira Sda C, Costa TV, Almeida Filho LC, Villanova MG, Souza FF, Teixeira AC, Figueiredo JF, Zucoloto S, Ramalho LN, Passos AD, Martinelli Ade L. Clinical, demographic and epidemiological characteristics of patients with hepatitis B followed at a university hospital in southeastern Brazil: predominance of HBeAg negative cases. Rev Soc Bras Med Trop 2011;44:13-7. [PMID: 21340400 DOI: 10.1590/s0037-86822011000100004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
361 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
362 Hsiao PC, Chen MK, Su SC, Ueng KC, Chen YC, Hsieh YH, Liu YF, Tsai HT, Yang SF. Hypoxia inducible factor-1alpha gene polymorphism G1790A and its interaction with tobacco and alcohol consumptions increase susceptibility to hepatocellular carcinoma. J Surg Oncol. 2010;102:163-169. [PMID: 20648588 DOI: 10.1002/jso.21539] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
363 Rhim H, Lim HK, Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma. World J Gastrointest Surg 2010; 2(4): 128-136 [PMID: 21160861 DOI: 10.4240/wjgs.v2.i4.128] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
364 Singhal G, Kumar G, Chan S, Fisher FM, Ma Y, Vardeh HG, Nasser IA, Flier JS, Maratos-Flier E. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab. 2018;13:56-66. [PMID: 29753678 DOI: 10.1016/j.molmet.2018.03.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
365 Kim Y, Ki H, Kim M, Cho D, Cho S, Joo Y, Kim H, Choi S, Rew J. Analysis of the clinical characteristics and prognostic factors of ruptured hepatocellular carcinoma. Korean J Hepatol 2009;15:148. [DOI: 10.3350/kjhep.2009.15.2.148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
366 Xia W, Ma X, Li X, Lu C, Yang X, Zhu Z, Yi J. Reversal effect of low-intensity ultrasound on adriamycin-resistant human hepatoma cells in vitro and in vivo. Int J Imaging Syst Technol 2014;24:23-8. [DOI: 10.1002/ima.22075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
367 Shih YL, Hsieh CB, Yan MD, Tsao CM, Hsieh TY, Liu CH, Lin YW. Frequent concomitant epigenetic silencing of SOX1 and secreted frizzled-related proteins (SFRPs) in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:551-559. [PMID: 23215838 DOI: 10.1111/jgh.12078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
368 Dertli R, Asil M, Biyik M, Karakarcayildiz A, Keskin M, Göktepe HM, Kayar Y, Ataseven H. Can Hematological Inflammatory Parameters Predict Mortality in Hepatocellular Carcinoma? J Gastrointest Cancer 2021;52:666-75. [PMID: 32617832 DOI: 10.1007/s12029-020-00448-2] [Reference Citation Analysis]
369 Zender L, Kubicka S. Androgen receptor and hepatocarcinogenesis: what do we learn from HCC mouse models? Gastroenterology. 2008;135:738-740. [PMID: 18692055 DOI: 10.1053/j.gastro.2008.07.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
370 Vogt TM, Goldstein ST, Kuartei S. Endemic hepatitis B virus infection and chronic liver disease mortality in the Republic of Palau, 1990–2002. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006;100:1130-4. [DOI: 10.1016/j.trstmh.2006.01.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
371 Ismail AM, Samuel P, Ramachandran J, Eapen CE, Kannangai R, Abraham P. Lamivudine Monotherapy in Chronic Hepatitis B Patients from the Indian Subcontinent: Antiviral Resistance Mutations and Predictive Factors of Treatment Response. Mol Diagn Ther 2014;18:63-71. [DOI: 10.1007/s40291-013-0054-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
372 Simonsen K, Rode A, Nicoll A, Villadsen G, Espelund U, Lim L, Angus P, Arachchi N, Vilstrup H, Nexo E, Grønbæk H. Vitamin B 12 and its binding proteins in hepatocellular carcinoma and chronic liver diseases. Scandinavian Journal of Gastroenterology 2014;49:1096-102. [DOI: 10.3109/00365521.2014.921325] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
373 Ji Z, Wang B. Identifying potential clinical syndromes of hepatocellular carcinoma using PSO-based hierarchical feature selection algorithm. Biomed Res Int 2014;2014:127572. [PMID: 24745007 DOI: 10.1155/2014/127572] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
374 Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011;13:842-8. [PMID: 20890660 DOI: 10.1007/s10903-010-9395-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
375 Langeswaran K, Gowthamkumar S, Vijayaprakash S, Revathy R, Balasubramanian MP. Influence of limonin on Wnt signalling molecule in HepG2 cell lines. J Nat Sci Biol Med. 2013;4:126-133. [PMID: 23633848 DOI: 10.4103/0976-9668.107276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
376 Choong CC, Venkatesh SK, Siew EP. Accuracy of routine clinical ultrasound for staging of liver fibrosis. J Clin Imaging Sci 2012;2:58. [PMID: 23230540 DOI: 10.4103/2156-7514.101000] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
377 Etzel RA. What the Primary Care Pediatrician Should Know about Syndromes Associated with Exposures to Mycotoxins. Current Problems in Pediatric and Adolescent Health Care 2006;36:282-305. [DOI: 10.1016/j.cppeds.2006.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
378 Yeh CB, Tsai HT, Chen YC, Kuo WH, Chen TY, Hsieh YH, Chou MC, Yang SF. Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol. 2010;102:264-270. [PMID: 20740585 DOI: 10.1002/jso.21623] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
379 Tarantino L, Busto G, Nasto A, Fristachi R, Cacace L, Talamo M, Accardo C, Bortone S, Gallo P, Tarantino P, Nasto RA, Di Minno MND, Ambrosino P. Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World J Gastroenterol 2017; 23(5): 906-918 [PMID: 28223736 DOI: 10.3748/wjg.v23.i5.906] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
380 Baffy G. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol 2013;1:131-7. [PMID: 26355775 DOI: 10.14218/JCTH.2013.00005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 0.8] [Reference Citation Analysis]
381 Feng Q, Stern JE, Hawes SE, Lu H, Jiang M, Kiviat NB. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 2010;88:287-92. [PMID: 20079733 DOI: 10.1016/j.yexmp.2010.01.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 5.1] [Reference Citation Analysis]
382 Tripathy A, Thakurela S, Sahu MK, Uthansingh K, Singh A, Narayan J, Ajay AK, Singh V, Kumari R. Fatty changes associated with N-Nitrosodiethylamine (DEN) induced hepatocellular carcinoma: a role of sonic hedgehog signaling pathway. Genes Cancer 2020;11:66-82. [PMID: 32577158 DOI: 10.18632/genesandcancer.203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
383 Albrecht T. HCC-Screening. Radiologe 2008;48:33-8. [DOI: 10.1007/s00117-007-1590-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
384 Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, Wu B, Lin C, Gao Z. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int. 2013;7:460-467. [PMID: 26201778 DOI: 10.1007/s12072-012-9415-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
385 Kuniholm MH, Lesi OA, Mendy M, Akano AO, Sam O, Hall AJ, Whittle H, Bah E, Goedert JJ, Hainaut P, Kirk GD. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect 2008;116:1553-7. [PMID: 19057710 DOI: 10.1289/ehp.11661] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
386 Abdel-hamid NM, Abouzied MM, Nazmy MH, Fawzy MA, Gerges AS. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumor Biol 2016;37:2539-46. [DOI: 10.1007/s13277-015-4025-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
387 Kwon H, Kim Y, Hwang J, Kim CY, Lee S, Moon S, Jeon B, Park P. Isolation and identification of an anticancer compound from the bark of Acer tegmentosum Maxim. Process Biochemistry 2014;49:1032-9. [DOI: 10.1016/j.procbio.2014.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
388 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
389 Chen F, He JL, Zheng M, Zhu HH, Li SP, Wang K, Zhang XX, Zhao YR, Wu SS, Chen Z. Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection. J Viral Hepat 2013;20:566-74. [DOI: 10.1111/jvh.12067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
390 Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song KJ, Park YN, Han KH. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61:1851-1859. [PMID: 25643638 DOI: 10.1002/hep.27735] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 13.4] [Reference Citation Analysis]
391 Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. Journal of Hepatology 2009;50:118-27. [DOI: 10.1016/j.jhep.2008.08.015] [Cited by in Crossref: 105] [Cited by in F6Publishing: 101] [Article Influence: 8.1] [Reference Citation Analysis]
392 Singh NA, Reau N. Management of hepatitis B virus. Journal of Antimicrobial Chemotherapy 2008;62:224-8. [DOI: 10.1093/jac/dkn188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
393 Nguyen NH, Nguyen V, Trinh HN, Lin B, Nguyen MH. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol 2013;11:565-71. [PMID: 23333662 DOI: 10.1016/j.cgh.2012.12.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
394 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
395 Chang CC, Chen SC, Hsieh YH, Chen YC, Chen TY, Chu YH, Ma HJ, Chou MC, Tsai HT, Yang SF. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med 2009;47:412-8. [PMID: 19327121 DOI: 10.1515/CCLM.2009.092] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
396 Zyoud SH. Global scientific trends on aflatoxin research during 1998-2017: a bibliometric and visualized study. J Occup Med Toxicol. 2019;14:27. [PMID: 31832075 DOI: 10.1186/s12995-019-0248-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
397 Rhim H, Lim HK, Kim YS, Choi D, Lee WJ. Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures. J Gastroenterol Hepatol. 2008;23:1492-1500. [PMID: 18713294 DOI: 10.1111/j.1440-1746.2008.05550.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
398 Kong NH, Chow PK. Conducting randomised controlled trials across countries with disparate levels of socio-economic development: the experience of the Asia-Pacific Hepatocellular Carcinoma Trials Group. Contemp Clin Trials 2013;36:682-6. [PMID: 23587539 DOI: 10.1016/j.cct.2013.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
399 Li F, Qiao CY, Gao S, Fan YC, Chen LY, Wang K. Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy. Free Radic Res 2018;52:455-64. [PMID: 29463155 DOI: 10.1080/10715762.2018.1443448] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
400 Meng J, Zhong J, Zhang H, Zhong W, Huang Z, Jin Y, Xu J. Pre-, peri-, and postoperative oral administration of branched-chain amino acids for primary liver cancer patients for hepatic resection: a systematic review. Nutr Cancer. 2014;66:517-522. [PMID: 24033366 DOI: 10.1080/01635581.2013.780628] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
401 Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World J Gastroenterol 2014; 20(34): 12039-12044 [PMID: 25232241 DOI: 10.3748/wjg.v20.i34.12039] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
402 Shimura T, Shibata M, Kofunato Y, Okada R, Ishigame T, Kimura T, Kenjo A, Marubashi S. Clinical significance of serum transthyretin level in patients with hepatocellular carcinoma: Transthyretin and prognosis of HCC. ANZ Journal of Surgery 2018;88:1328-32. [DOI: 10.1111/ans.14458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
403 Mohan CD, Kim C, Siveen KS, Manu KA, Rangappa S, Chinnathambi A, Alharbi SA, Rangappa KS, Kumar AP, Ahn KS. Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma. IUBMB Life 2021;73:1348-62. [PMID: 34514729 DOI: 10.1002/iub.2555] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. Cancer Lett. 2006;240:157-169. [PMID: 16239065 DOI: 10.1016/j.canlet.2005.08.031] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
405 Mogahed MM, Zytoon AA, Eysa B, Manaa M, Abdellatif W. Outcome of Laparoscopic Assisted Percutaneous Microwave Ablation for Exophytic Versus Non-exophytic Hepatocellular Carcinoma. J Gastrointest Cancer 2021;52:892-8. [PMID: 32869147 DOI: 10.1007/s12029-020-00477-x] [Reference Citation Analysis]
406 Ramesh V, Ganesan K. Integrative functional genomic analysis unveils the differing dysregulated metabolic processes across hepatocellular carcinoma stages. Gene 2016;588:19-29. [PMID: 27107678 DOI: 10.1016/j.gene.2016.04.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
407 Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011;26:628-638. [PMID: 21323729 DOI: 10.1111/j.1440-1746.2011.06695.x] [Cited by in Crossref: 172] [Cited by in F6Publishing: 168] [Article Influence: 15.6] [Reference Citation Analysis]
408 Yang H, Xiong F, Wei X, Yang Y, McNutt MA, Zhou R. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 2010;294:236-244. [PMID: 20202745 DOI: 10.1016/j.canlet.2010.02.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
409 Zaghloul RA, Elsherbiny NM, Kenawy HI, El-karef A, Eissa LA, El-shishtawy MM. Hepatoprotective effect of hesperidin in hepatocellular carcinoma: Involvement of Wnt signaling pathways. Life Sciences 2017;185:114-25. [DOI: 10.1016/j.lfs.2017.07.026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
410 Mitrea D, Badea R, Mitrea P, Brad S, Nedevschi S. Hepatocellular Carcinoma Automatic Diagnosis within CEUS and B-Mode Ultrasound Images Using Advanced Machine Learning Methods. Sensors (Basel) 2021;21:2202. [PMID: 33801125 DOI: 10.3390/s21062202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
411 Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. Br J Cancer 2021;124:407-13. [PMID: 33071284 DOI: 10.1038/s41416-020-01116-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
412 Lee CH, Brubaker LM, Gerber DA, Ku YM, Kim YH, Shin SS, Semelka RC. MRI findings of recurrent hepatocellular carcinoma after liver transplantation: preliminary results. J Magn Reson Imaging. 2011;33:1399-1405. [PMID: 21591009 DOI: 10.1002/jmri.22326] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
413 Bi L, Yan X, Chen W, Gao J, Qian L, Qiu S. Antihepatocellular Carcinoma Potential of Tetramethylpyrazine Induces Cell Cycle Modulation and Mitochondrial-Dependent Apoptosis: Regulation of p53 Signaling Pathway in HepG2 Cells In Vitro. Integr Cancer Ther. 2016;15:226-236. [PMID: 27179035 DOI: 10.1177/1534735416637424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
414 Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol. 2011;2011:974514. [PMID: 21994880 DOI: 10.4061/2011/974514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
415 Peng Q, Chunfang G, Meng F, Qiang J, Yunpeng Z, Yan L, Xiaojuan S. Establishment of a real-time PCR for quantifying transforming growth factor beta1 in blood of hepatocellular carcinoma patients. Journal of Medical Colleges of PLA 2008;23:228-36. [DOI: 10.1016/s1000-1948(08)60047-7] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
416 Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol. 2009;51:810-820. [PMID: 19545926 DOI: 10.1016/j.jhep.2009.05.008] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 7.3] [Reference Citation Analysis]
417 Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 2009; 15(5): 578-582 [PMID: 19195059 DOI: 10.3748/wjg.15.578] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
418 Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology. 2010;52:1922-1933. [PMID: 20814897 DOI: 10.1002/hep.23898] [Cited by in Crossref: 57] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
419 Tariq F, Khan W, Ahmad W, Riaz SK, Khan M, Sherwani S, Haque S, Malik MFA, Iftikhar MJ, Khan S, Haq F. Effect of MHC Linked 7-Gene Signature on Delayed Hepatocellular Carcinoma Recurrence. J Pers Med 2021;11:1129. [PMID: 34834481 DOI: 10.3390/jpm11111129] [Reference Citation Analysis]
420 Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology 2012;56:397-405. [DOI: 10.1016/j.jhep.2011.05.026] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
421 Marrero JA. Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers. Journal of Hepatology 2009;50:659-61. [DOI: 10.1016/j.jhep.2009.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
422 Xu XY, Wang WS, Zhang QM, Li JL, Sun JB, Qin TT, Liu HB. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. World J Clin Cases 2019; 7(15): 2022-2037 [PMID: 31423434 DOI: 10.12998/wjcc.v7.i15.2022] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
423 Avellini C, Orsaria M, Baccarani U, Adani GL, Lorenzin D, Bresadola V, Bresadola F, Beltrami CA. Apurinic apyrimidinic endonuclease/redox effector factor 1 immunoreactivity and grading in hepatocellular carcinoma risk of relapse after liver transplantation. Transplant Proc. 2010;42:1204-1208. [PMID: 20534262 DOI: 10.1016/j.transproceed.2010.03.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
424 Lin YW, Shih YL, Lien GS, Suk FM, Hsieh CB, Yan MD. Promoter methylation of SFRP3 is frequent in hepatocellular carcinoma. Dis Markers 2014;2014:351863. [PMID: 24591760 DOI: 10.1155/2014/351863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
425 Ribes J, Clèries R, Esteban L, Moreno V, Bosch FX. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol. 2008;49:233-242. [PMID: 18571275 DOI: 10.1016/j.jhep.2008.04.016] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
426 Han B, Wu LQ, Ma X, Wang ZH, Li JP, Bi CY, Yong S. Synergistic effect of IFN-γ gene on LIGHT-induced apoptosis in HepG2 cells via down regulation of Bcl-2. Artif Cells Blood Substit Immobil Biotechnol. 2011;39:228-238. [PMID: 21117871 DOI: 10.3109/10731199.2010.538403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
427 Zhang XX, Li MR, Cao Y, Zhang RW, Zhang Y, Li F, Xi HL, Xu XY. Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study. Medicine (Baltimore) 2016;95:e2614. [PMID: 26825915 DOI: 10.1097/MD.0000000000002614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
428 Dai XM, Yang SL, Zheng XM, Chen GG, Chen J, Zhang T. CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis. Oncol Lett 2018;15:2985-91. [PMID: 29435028 DOI: 10.3892/ol.2017.7704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
429 Shih YL, Shyu RY, Hsieh CB, Lai HC, Liu KY, Chu TY, Lin YW. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 2006;107:579-590. [PMID: 16795071 DOI: 10.1002/cncr.22023] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 4.8] [Reference Citation Analysis]
430 Chien MH, Yeh CB, Li YC, Wei LH, Chang JH, Peng YT, Yang SF, Kuo WH. Relationship of interleukin-8 gene polymorphisms with hepatocellular carcinoma susceptibility and pathological development. J Surg Oncol 2011;104:798-803. [PMID: 21780129 DOI: 10.1002/jso.22037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
431 Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 2008;147:23-33. [PMID: 17574577 DOI: 10.1016/j.jss.2007.04.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
432 Lee NY, Choi HK, Shim JH, Kang KW, Dong Z, Choi HS. The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation. Carcinogenesis. 2009;30:671-681. [PMID: 19168580 DOI: 10.1093/carcin/bgp027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
433 Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4:252-261. [PMID: 16527686 DOI: 10.1016/j.cgh.2006.01.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
434 Vezali E, Aghemo A, Lampertico P, Colombo M. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? Clin Res Hepatol Gastroenterol 2011;35:455-64. [PMID: 21435968 DOI: 10.1016/j.clinre.2011.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
435 Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19-26. [PMID: 18538135 DOI: 10.1016/j.cca.2008.05.010] [Cited by in Crossref: 136] [Cited by in F6Publishing: 126] [Article Influence: 9.7] [Reference Citation Analysis]
436 Parisi I, Tsochatzis E, Wijewantha H, Rodríguez-Perálvarez M, De Luca L, Manousou P, Fatourou E, Pieri G, Papastergiou V, Davies N. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014;20:1327-1335. [PMID: 25088400 DOI: 10.1002/lt.23969] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
437 Dong B, Lyu G, Chen Y, Lin G, Wang H, Qin R, Gu J. Comparison of two-dimensional shear wave elastography, magnetic resonance elastography, and three serum markers for diagnosing fibrosis in patients with chronic hepatitis B: a meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1077-89. [PMID: 33487039 DOI: 10.1080/17474124.2021.1880894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
438 Zubaidah RM, Tan GS, Tan SBE, Lim SG, Lin Q, Chung MCM. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008;8:5086-96. [DOI: 10.1002/pmic.200800322] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
439 Ma S, Chan KW, Guan X. In Search of Liver Cancer Stem Cells. Stem Cell Rev 2008;4:179-92. [DOI: 10.1007/s12015-008-9035-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
440 Hennig M, Yip-Schneider MT, Klein P, Wentz S, Matos JM, Doyle C, Choi J, Wu H, O'Mara A, Menze A, Noble S, McKillop IH, Schmidt CM. Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinoma. J Surg Res 2009;154:187-95. [PMID: 19321179 DOI: 10.1016/j.jss.2008.11.836] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
441 Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, Chen Z, Meng Z. Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma. Biosci Rep 2020;40:BSR20194240. [PMID: 32579175 DOI: 10.1042/BSR20194240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Guerrero-Preston R, Siegel A, Renz J, Vlahov D, Neugut A. HCV infection and cryptogenic cirrhosis are risk factors for hepatocellular carcinoma among Latinos in New York City. J Community Health 2009;34:500-5. [PMID: 19705261 DOI: 10.1007/s10900-009-9184-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
443 Liang J, Jiang MJ, Deng X, Xiao Zhou X. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study. Hepat Mon. 2013;13:e7862. [PMID: 24032045 DOI: 10.5812/hepatmon.7862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
444 Wang B, Li B, Dai Z, Ren S, Bai M, Wang Z, Li Z, Lin S, Wang Z, Huang N. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells. Int J Biochem Cell Biol. 2014;55:98-108. [PMID: 25168696 DOI: 10.1016/j.biocel.2014.08.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
445 Ramzy II, Omran DA, Hamad O, Shaker O, Abboud A. Evaluation of serum LINE-1 hypomethylation as a prognostic marker for hepatocellular carcinoma. Arab J Gastroenterol 2011;12:139-42. [PMID: 22055592 DOI: 10.1016/j.ajg.2011.07.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
446 Li W, Dong C. Polymorphism in asparagine synthetase is associated with overall survival of hepatocellular carcinoma patients. BMC Gastroenterol 2017;17:79. [PMID: 28629319 DOI: 10.1186/s12876-017-0635-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
447 Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894. [PMID: 23233864 DOI: 10.5812/hepatmon.6894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
448 Gao S, Li XY, Fan YC, Sun FK, Han LY, Li F, Ji XF, Wang K. A noninvasive model to predict liver histology in HBeAg-positive chronic hepatitis B with alanine aminotransferase ≤ 2upper limit of normal. J Gastroenterol Hepatol 2017;32:215-20. [PMID: 27207016 DOI: 10.1111/jgh.13452] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
449 Dimzova M, Bosilkovski M, Kondova-Topuzovska I, Gaseva M, Toshevki B, Petreska B, Jakimovski D. Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B. Open Access Maced J Med Sci 2019;7:2068-74. [PMID: 31456827 DOI: 10.3889/oamjms.2019.623] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
450 Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:275-81. [PMID: 19690886 DOI: 10.1007/s00432-009-0659-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
451 Kalogeridi MA, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, Kouloulias V. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol 2015; 7(1): 101-112 [PMID: 25625001 DOI: 10.4254/wjh.v7.i1.101] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 11.3] [Reference Citation Analysis]
452 Macaluso FS, Calvaruso V, Craxì A. Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. Future Microbiol 2015;10:977-88. [PMID: 26059621 DOI: 10.2217/fmb.15.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
453 Chien MH, Yeh KT, Li YC, Hsieh YH, Lin CH, Weng MS, Kuo WH, Yang SF. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. J Surg Oncol. 2011;104:299-304. [PMID: 21462191 DOI: 10.1002/jso.21929] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
454 DU J, Qian X, Liu B. Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature. Oncol Lett 2013;5:381-5. [PMID: 23255954 DOI: 10.3892/ol.2012.974] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
455 Maimone S, Calvaruso V, Pleguezuelo M, Squadrito G, Amaddeo G, Jacobs M, Khanna P, Raimondo G, Dusheiko G. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. J Viral Hepat. 2009;16:769-774. [PMID: 19709363 DOI: 10.1111/j.1365-2893.2009.01120.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
456 Greene CM, Varley RB, Lawless MW. MicroRNAs and liver cancer associated with iron overload: Therapeutic targets unravelled. World J Gastroenterol 2013; 19(32): 5212-5226 [PMID: 23983424 DOI: 10.3748/wjg.v19.i32.5212] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
457 Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci. 2010;55:2744-2755. [PMID: 20339916 DOI: 10.1007/s10620-010-1184-7] [Cited by in Crossref: 118] [Cited by in F6Publishing: 114] [Article Influence: 9.8] [Reference Citation Analysis]
458 Gao S, Huan S, Han L, Li F, Ji X, Li X, Fan Y, Wang K. Overexpression of serum sST2 is associated with poor prognosis in acute-on-chronic hepatitis B liver failure. Clinics and Research in Hepatology and Gastroenterology 2015;39:315-23. [DOI: 10.1016/j.clinre.2014.10.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
459 Schutt D, O’rourke A, Will J, Haemmerich D. Biopotential as predictor of ablation zone size during radiofrequency tumor ablation. Scientia Iranica 2011;18:1511-5. [DOI: 10.1016/j.scient.2011.08.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
460 Cuevas EP, Escribano O, Monserrat J, Martínez-Botas J, Sánchez MG, Chiloeches A, Hernández-Breijo B, Sánchez-Alonso V, Román ID, Fernández-Moreno MD. RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor-alpha-induced cell death in hepatocarcinoma cancer cell lines. J Cell Biochem. 2009;108:1292-1301. [PMID: 19795387 DOI: 10.1002/jcb.22359] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
461 Díaz C, Vargas E, Gätjens-Boniche O. Cytotoxic effect induced by retinoic acid loaded into galactosyl-sphingosine containing liposomes on human hepatoma cell lines. Int J Pharm. 2006;325:108-115. [PMID: 16870366 DOI: 10.1016/j.ijpharm.2006.06.034] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
462 Maillard E. [Epidemiology, natural history and pathogenesis of hepatocellular carcinoma]. Cancer Radiother 2011;15:3-6. [PMID: 21239205 DOI: 10.1016/j.canrad.2010.11.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
463 Theve EJ, Feng Y, Taghizadeh K, Cormier KS, Bell DR, Fox JG, Rogers AB. Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus. Infect Immun 2008;76:4071-8. [PMID: 18559427 DOI: 10.1128/IAI.00401-08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
464 Chen YL, Tseng HS, Kuo WH, Yang SF, Chen DR, Tsai HT. Glutathione S-Transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. BMC Med Genet. 2010;11:46. [PMID: 20331903 DOI: 10.1186/1471-2350-11-46] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
465 Abdelaziz AO, Abdelhalim H, Elsharkawy A, Shousha HI, Abdelmaksoud AH, Soliman ZA, Seif MI, Sayed DB, Farouk MH, Elbaz TM, Nabeel MM. Liver stiffness measurement changes following hepatocellular carcinoma treatment with percutaneous microwave ablation or transarterial chemoembolization: a cohort study. Eur J Gastroenterol Hepatol 2019;31:685-91. [PMID: 30640743 DOI: 10.1097/MEG.0000000000001343] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
466 Uccello M, Malaguarnera G, Pelligra EM, Biondi A, Basile F, Motta M. Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian J Med Paediatr Oncol 2011;32:71-5. [PMID: 22174493 DOI: 10.4103/0971-5851.89775] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
467 Nishanth RP, Ramakrishna B, Jyotsna RG, Roy KR, Reddy GV, Reddy PK, Reddanna P. C-Phycocyanin inhibits MDR1 through reactive oxygen species and cyclooxygenase-2 mediated pathways in human hepatocellular carcinoma cell line. European Journal of Pharmacology 2010;649:74-83. [DOI: 10.1016/j.ejphar.2010.09.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
468 Kim Y, Ejaz A, Tayal A, Spolverato G, Bridges JF, Anders RA, Pawlik TM. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer 2014;120:3058-65. [PMID: 24917245 DOI: 10.1002/cncr.28843] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
469 Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment Options for Hepatobiliary and Pancreatic Cancer. Mayo Clinic Proceedings 2007;82:628-37. [DOI: 10.4065/82.5.628] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
470 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
471 Wan L, Guo L, Hu Y, Huang H, Zhang M, Xu K, De G, Zheng F, Wu Z, Hu C, Wen Z. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer. Clin Biochem 2021;89:44-50. [PMID: 33309517 DOI: 10.1016/j.clinbiochem.2020.12.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
472 Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M. Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process. Journal of Hepatology 2015;62:855-62. [DOI: 10.1016/j.jhep.2014.11.014] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 11.6] [Reference Citation Analysis]
473 Güzelcan EA, Baxendale IR, Cetin-Atalay R, Baumann M. Synthesis of new derivatives of boehmeriasin A and their biological evaluation in liver cancer. Eur J Med Chem 2019;166:243-55. [PMID: 30716712 DOI: 10.1016/j.ejmech.2019.01.056] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
474 Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231-238. [PMID: 20820869 DOI: 10.1007/s11060-010-0383-6] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 7.0] [Reference Citation Analysis]
475 Huang PJ, Chiu CC, Hsiao MH, Yow JL, Tzang BS, Hsu TC. Potential of antiviral drug oseltamivir for the treatment of liver cancer. Int J Oncol 2021;59:109. [PMID: 34859259 DOI: 10.3892/ijo.2021.5289] [Reference Citation Analysis]
476 Jablonski EM, Mattocks MA, Sokolov E, Koniaris LG, Hughes FM, Fausto N, Pierce RH, McKillop IH. Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett. 2007;250:36-46. [PMID: 17084522 DOI: 10.1016/j.canlet.2006.09.013] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 5.4] [Reference Citation Analysis]
477 Ashoori N, Paprottka P, Trumm C, Bamberg F, Kolligs FT, Rentsch M, Reiser MF, Jakobs TF. Multimodality treatment with conventional transcatheter arterial chemoembolization and radiofrequency ablation for unresectable hepatocellular carcinoma. Digestion. 2012;85:18-26. [PMID: 22156507 DOI: 10.1159/000334714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
478 Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. Vaccines. Elsevier; 2013. pp. 205-34. [DOI: 10.1016/b978-1-4557-0090-5.00025-2] [Cited by in Crossref: 14] [Article Influence: 1.6] [Reference Citation Analysis]
479 Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol 2014;35:2497-502. [PMID: 24163059 DOI: 10.1007/s13277-013-1330-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
480 Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34:1630-1636. [PMID: 20975341 DOI: 10.1097/pas.0b013e3181f31caa] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
481 Yokoyama Y, Nagino M, Nimura Y. Which Gender is Better Positioned in the Process of Liver Surgery? Male or Female? Surg Today 2007;37:823-30. [DOI: 10.1007/s00595-007-3508-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
482 Merle P. [Epidemiology, natural history and pathogenesis of hepatocellular carcinoma]. Cancer Radiother 2005;9:452-7. [PMID: 16226912 DOI: 10.1016/j.canrad.2005.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
483 Dyson JK, Waller J, Turley A, Michael E, Moses S, Valappil M, Hudson M, Bassendine M, McPherson S. Hepatitis B in pregnancy. Frontline Gastroenterol 2014;5:111-7. [PMID: 24683447 DOI: 10.1136/flgastro-2013-100361] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
484 Kidner T, Dai M, Adusumilli PS, Fong Y. Advances in experimental and translational research in the treatment of hepatocellular carcinoma. Surg Oncol Clin N Am 2008;17:377-89, ix. [PMID: 18375358 DOI: 10.1016/j.soc.2008.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
485 Wengert GJ, Bickel H, Breitenseher J, Ba-Ssalamah A. [Primary liver tumors : hepatocellular versus intrahepatic cholangiocellular carcinoma]. Radiologe 2015;55:27-35. [PMID: 25575724 DOI: 10.1007/s00117-014-2705-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
486 Becker AK, Tso DK, Harris AC, Malfair D, Chang SD. Extrahepatic metastases of hepatocellular carcinoma: A spectrum of imaging findings. Can Assoc Radiol J 2014;65:60-6. [PMID: 24239313 DOI: 10.1016/j.carj.2013.05.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
487 Lyu X, Liu K, Chen Y, Wang Z, Yao J, Cai G, Jiang Z, Wang Z, Jiang J, Gu H. Analysis of Risk Factors Associated with the Development of Hepatocellular Carcinoma in Chronic HBV-Infected Chinese: A Meta-Analysis. Int J Environ Res Public Health 2016;13:E604. [PMID: 27322300 DOI: 10.3390/ijerph13060604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
488 Kaufmann R, Mussbach F, Henklein P, Settmacher U. Proteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells. J Cancer Res Clin Oncol. 2011;137:965-973. [PMID: 21125404 DOI: 10.1007/s00432-010-0961-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
489 Montomoli J, Erichsen R, Nørgaard M, Høyer M, Hansen JB, Jacobsen JB. Survival of patients with primary liver cancer in central and northern Denmark, 1998-2009. Clin Epidemiol 2011;3 Suppl 1:3-10. [PMID: 21814464 DOI: 10.2147/CLEP.S20623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
490 Shalably NM, Badawi R, Hawash N, Abd-elsalam S, Elkhalawany W, Hameed AAE, Alkassas GE. Evaluation of Fucosylated Haptoglobin as a Diagnostic Biomarker for Hepatocellular Carcinoma in Egypt. TOBIOMJ 2019;9:31-7. [DOI: 10.2174/1875318301909010031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
491 Nomura F, Sogawa K, Noda K, Seimiya M, Matsushita K, Miura T, Tomonaga T, Yoshitomi H, Imazeki F, Takizawa H. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2012;421:837-843. [PMID: 22554520 DOI: 10.1016/j.bbrc.2012.04.099] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
492 Casanovas-Taltavull T, Ribes J, Berrozpe A, Jordan S, Casanova A, Sancho C, Valls C, Bosch FX. Patient with hepatocellular carcinoma related to prior acute arsenic intoxication and occult HBV: Epidemiological, clinical and therapeutic results after 14 years of follow-up. World J Gastroenterol 2006; 12(12): 1972-1974 [PMID: 16610011 DOI: 10.3748/wjg.v12.i12.1972] [Reference Citation Analysis]
493 Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford). 2011;13:168-173. [PMID: 21309933 DOI: 10.1111/j.1477-2574.2010.00261.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 100] [Article Influence: 10.2] [Reference Citation Analysis]
494 Shen D, Zheng J, Cui X, Chen Y, He Q, Lv R, Li Z, Zhao S. Analysis of cholyglycine acid as a biomarker for the early diagnosis of liver disease by fluorescence polarization immunoassay. Sensors and Actuators B: Chemical 2018;256:846-52. [DOI: 10.1016/j.snb.2017.10.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
495 Dohi O, Yasui K, Gen Y, Takada H, Endo M, Tsuji K, Konishi C, Yamada N, Mitsuyoshi H, Yagi N. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42:411-418. [PMID: 23229728 DOI: 10.3892/ijo.2012.1724] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
496 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol 2015; 7(11): 1553-1561 [PMID: 26085914 DOI: 10.4254/wjh.v7.i11.1553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
497 Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, Li J, Ehman RL. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? Radiology. 2014;273:88-98. [PMID: 24893048 DOI: 10.1148/radiol.14132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
498 Weng CJ, Tsai CM, Chen YC, Hsieh YH, Lin CW, Liu YF, Su SC, Chen MK, Yang SF. Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010;17:3394-401. [PMID: 20706793 DOI: 10.1245/s10434-010-1124-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
499 Wu X, Xin Z, Zhang W, Zheng S, Wu J, Chen K, Wang H, Zhu X, Li Z, Duan Z, Li H, Liu Y. A missense polymorphism in ATF6 gene is associated with susceptibility to hepatocellular carcinoma probably by altering ATF6 level: ATF6 polymorphism and HCC. Int J Cancer 2014;135:61-8. [DOI: 10.1002/ijc.28649] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
500 Giliberti G, Ibba C, Marongiu E, Loddo R, Tonelli M, Boido V, Laurini E, Posocco P, Fermeglia M, Pricl S. Synergistic experimental/computational studies on arylazoenamine derivatives that target the bovine viral diarrhea virus RNA-dependent RNA polymerase. Bioorg Med Chem 2010;18:6055-68. [PMID: 20638852 DOI: 10.1016/j.bmc.2010.06.065] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
501 Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 [PMID: 26478678 DOI: 10.3748/wjg.v21.i38.10874] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
502 Jo W, Yu ES, Chang M, Park HK, Choi HJ, Ryu JE, Jang S, Lee HJ, Jang JJ, Son WC. Metformin inhibits early stage diethylnitrosamine‑induced hepatocarcinogenesis in rats. Mol Med Rep 2016;13:146-52. [PMID: 26548419 DOI: 10.3892/mmr.2015.4513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
503 Samie HAA, Saeed M, Faisal SM, Kausar MA, Kamal MA. Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma. CDM 2019;20:283-91. [DOI: 10.2174/1389200220666190308134351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
504 Abd El Moety HA, Maharem DA, Gomaa SH. Serotonin: is it a marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients? Alexandria Journal of Medicine 2013;49:369-78. [DOI: 10.1016/j.ajme.2013.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
505 Saad-Hussein A, Taha MM, Beshir S, Shahy EM, Shaheen W, Elhamshary M. Carcinogenic effects of aflatoxin B1 among wheat handlers. Int J Occup Environ Health 2014;20:215-9. [PMID: 25000109 DOI: 10.1179/2049396714Y.0000000069] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
506 Negm O, Abou Saif S, El Gharib M, Yousef M, Abd-Elsalam S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2017;29:317-21. [PMID: 27893491 DOI: 10.1097/MEG.0000000000000790] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
507 McDermott AM, Heneghan HM, Miller N, Kerin MJ. The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res 2011;28:3016-29. [PMID: 21818713 DOI: 10.1007/s11095-011-0550-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
508 Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29:130-143. [PMID: 18061252 DOI: 10.1016/j.mam.2007.09.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 4.4] [Reference Citation Analysis]
509 Gehrau R, Mas V, Archer KJ, Maluf D. Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. Expert Rev Gastroenterol Hepatol. 2011;5:539-552. [PMID: 21780900 DOI: 10.1586/egh.11.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
510 Morris-stiff G, Gomez D, de Liguori Carino N, Prasad K. Surgical management of hepatocellular carcinoma: Is the jury still out? Surgical Oncology 2009;18:298-321. [DOI: 10.1016/j.suronc.2008.08.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
511 Orlacchio A, Bolacchi F, Chegai F, Bergamini A, Costanzo E, Del Giudice C, Angelico M, Simonetti G. Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm. Radiol Med. 2014;119:298-308. [PMID: 24277510 DOI: 10.1007/s11547-013-0339-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
512 Shao S, Liang Y, Kuang S, Chen J, Shan Q, Yang H, Zhang Y, Wang B, J Fowler K, Wang J, B Sirlin C. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. Bosn J Basic Med Sci 2020;20:401-10. [PMID: 31999940 DOI: 10.17305/bjbms.2019.4576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
513 Maehara N, Arai S, Mori M, Iwamura Y, Kurokawa J, Kai T, Kusunoki S, Taniguchi K, Ikeda K, Ohara O, Yamamura KI, Miyazaki T. Circulating AIM prevents hepatocellular carcinoma through complement activation. Cell Rep. 2014;9:61-74. [PMID: 25284781 DOI: 10.1016/j.celrep.2014.08.058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
514 Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett 2013;6:821-8. [PMID: 24137418 DOI: 10.3892/ol.2013.1435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
515 Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Garcia G, Ahmed A, Keeffe EB, Nguyen MH. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-70. [PMID: 22941429 DOI: 10.1097/MCG.0b013e31825ceed9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
516 Kang J, Cho JH, Suh CW, Lee DH, Oh HB, Sohn YH, Chi HS, Park CJ, Jang SS, Lee KH. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol. 2011;90:159-164. [PMID: 20821327 DOI: 10.1007/s00277-010-1055-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
517 Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176-182. [PMID: 20006394 DOI: 10.1016/j.jhep.2009.11.007] [Cited by in Crossref: 184] [Cited by in F6Publishing: 168] [Article Influence: 14.2] [Reference Citation Analysis]
518 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 505] [Article Influence: 53.6] [Reference Citation Analysis]
519 Palmieri VO, Grattagliano I, Minerva F, Pollice S, Palasciano G, Portincasa P. Liver Function as Assessed by Breath Tests in Patients With Hepatocellular Carcinoma. Journal of Surgical Research 2009;157:199-207. [DOI: 10.1016/j.jss.2008.09.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
520 McPherson S, Valappil M, Moses SE, Eltringham G, Miller C, Baxter K, Chan A, Shafiq K, Saeed A, Qureshi R. Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. J Viral Hepat. 2013;20:638-644. [PMID: 23910648 DOI: 10.1111/jvh.12084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
521 Kerdsuknirun J, Vilaichone V, Vilaichone RK. Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand. Asian Pac J Cancer Prev 2018;19:3301-5. [PMID: 30486641 DOI: 10.31557/APJCP.2018.19.11.3301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
522 Gebremeskel T, Beshah T, Tesfaye M, Beletew B, Mengesha A, Getie A. Assessment of Knowledge and Practice on Hepatitis B Infection Prevention and Associated Factors among Health Science Students in Woldia University, Northeast Ethiopia. Adv Prev Med 2020;2020:9421964. [PMID: 32328311 DOI: 10.1155/2020/9421964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
523 Walker EJ, Rosenberg SA, Wands JR, Kim M. Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma. For Immunopathol Dis Therap 2011;2:195-204. [PMID: 21984963 DOI: 10.1615/ForumImmunDisTher.v2.i2.110] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
524 O’Rourke AP, Lazebnik M, Bertram JM, Converse MC, Hagness SC, Webster JG, Mahvi DM. Dielectric properties of human normal, malignant and cirrhotic liver tissue: in vivo and ex vivo measurements from 0.5 to 20 GHz using a precision open-ended coaxial probe. Phys Med Biol. 2007;52:4707-4719. [PMID: 17634659 DOI: 10.1088/0031-9155/52/15/022] [Cited by in Crossref: 164] [Cited by in F6Publishing: 84] [Article Influence: 10.9] [Reference Citation Analysis]
525 Gupta N, Rastogi A, Bihari C. Steatohepatitic hepatocellular carcinoma-a case report with literature review. Indian J Surg Oncol 2014;5:161-3. [PMID: 25114474 DOI: 10.1007/s13193-014-0297-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Wang B, Chou YE, Lien MY, Su CM, Yang SF, Tang CH. Impacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development. Int J Med Sci. 2017;14:880-884. [PMID: 28824325 DOI: 10.7150/ijms.19620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
527 Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK, Pinson CW. Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma. Ann Surg Oncol 2010;17:3104-11. [PMID: 20585872 DOI: 10.1245/s10434-010-1181-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
528 Hu ZD, Jiang Y, Sun HM, Wang JW, Zhai LL, Yin ZQ, Yan J. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers. Biomed Res Int 2021;2021:2676745. [PMID: 33490265 DOI: 10.1155/2021/2676745] [Reference Citation Analysis]
529 van Tienderen GS, Groot Koerkamp B, IJzermans JNM, van der Laan LJW, Verstegen MMA. Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment. Cancers (Basel). 2019;11. [PMID: 31683901 DOI: 10.3390/cancers11111706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
530 Edling CE, Selvaggi F, Ghonaim R, Maffucci T, Falasca M. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther. 2014;15:524-532. [PMID: 24521981 DOI: 10.4161/cbt.28018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
531 Coenen S, van Meer S, Vrolijk JM, Richter C, van Erpecum KJ, Mostert MC, Veldhuijzen IK, Reijnders JG, van Soest H, Dirksen K, Drenth JP, Koene RP, Bosschart M, Friederich P, Ter Borg MJ, Daemen RH, Arends JE, Verhagen MA, Schout C, Spanier BW. Clinical impact of five large-scale screening projects for chronic hepatitis B in Chinese migrants in the Netherlands. Liver Int 2016;36:1425-32. [PMID: 27001619 DOI: 10.1111/liv.13125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
532 Matsuura K, Isogawa M, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis B virus infection. J Med Virol. 2016;88:371-379. [PMID: 26255971 DOI: 10.1002/jmv.24350] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
533 Chu R, Mo G, Duan Z, Huang M, Chang J, Li X, Liu P. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal. 2014;12:45. [PMID: 25012758 DOI: 10.1186/s12964-014-0045-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
534 Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, Chernyak V, Bashir MR, Kono Y, Do RK, Mitchell DG, Kamaya A, Hecht EM, Sirlin CB. 2017 Version of LI-RADS for CT and MR Imaging: An Update. Radiographics. 2017;37:1994-2017. [PMID: 29131761 DOI: 10.1148/rg.2017170098] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 31.0] [Reference Citation Analysis]
535 Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013;58:1181-1187. [PMID: 23395691 DOI: 10.1016/j.jhep.2013.01.039] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 9.1] [Reference Citation Analysis]
536 Han J, Li J, Qian Y, Liu W, Liang J, Huang Z, Wang S, Zhao C. Identification of plasma miR-148a as a noninvasive biomarker for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2019;43:585-93. [PMID: 30824368 DOI: 10.1016/j.clinre.2018.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
537 Motola-kuba D, Zamora-valdés D, Uribe M, Méndez-sánchez N. Hepatocellular carcinoma. An overview. Annals of Hepatology 2006;5:16-24. [DOI: 10.1016/s1665-2681(19)32034-4] [Cited by in Crossref: 88] [Article Influence: 5.5] [Reference Citation Analysis]
538 Kang HJ, Kim IH, Sung CO, Shim JH, Yu E. Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma. Virchows Arch 2015;466:403-13. [DOI: 10.1007/s00428-014-1709-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
539 Jain S, Chang TT, Chen S, Boldbaatar B, Clemens A, Lin SY, Yan R, Hu CT, Guo H, Block TM, Song W, Su YH. Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Sci Rep 2015;5:10478. [PMID: 26000761 DOI: 10.1038/srep10478] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
540 Key TJ, Spencer EA. Carbohydrates and cancer: an overview of the epidemiological evidence. Eur J Clin Nutr. 2007;61 Suppl 1:S112-S121. [PMID: 17992182 DOI: 10.1038/sj.ejcn.1602941] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
541 Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 2016;29:77-89. [PMID: 27429211 DOI: 10.1016/j.coph.2016.07.005] [Cited by in Crossref: 100] [Cited by in F6Publishing: 101] [Article Influence: 16.7] [Reference Citation Analysis]
542 García A, Ihrig MM, Fry RC, Feng Y, Xu S, Boutin SR, Rogers AB, Muthupalani S, Samson LD, Fox JG. Genetic susceptibility to chronic hepatitis is inherited codominantly in Helicobacter hepaticus-infected AB6F1 and B6AF1 hybrid male mice, and progression to hepatocellular carcinoma is linked to hepatic expression of lipogenic genes and immune function-associated networks. Infect Immun. 2008;76:1866-1876. [PMID: 18285497 DOI: 10.1128/IAI.01044-07] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
543 Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat. 2011;18:e475-e481. [PMID: 21914066 DOI: 10.1111/j.1365-2893.2011.01479.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
544 Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006;44:1465-77. [PMID: 17133484 DOI: 10.1002/hep.21437] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.5] [Reference Citation Analysis]
545 Allain J, Opare-sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol 2016;13:643-53. [DOI: 10.1038/nrgastro.2016.138] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
546 Jeong A, Kim JH, Lee HJ, Kim SH. Reactive oxygen species dependent phosphorylation of the liver kinase B1/AMP activated protein kinase/ acetyl-CoA carboxylase signaling is critically involved in apoptotic effect of lambertianic acid in hepatocellular carcinoma cells. Oncotarget 2017;8:70116-29. [PMID: 29050265 DOI: 10.18632/oncotarget.19592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
547 Hui KM. Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications. Cancer Lett 2009;286:96-102. [PMID: 19095350 DOI: 10.1016/j.canlet.2008.11.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
548 Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin. 2010;31:1165-1171. [PMID: 20676120 DOI: 10.1038/aps.2010.94] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
549 Kanazir M, Boricic I, Delic D, Tepavcevic DK, Knezevic A, Jovanovic T, Pekmezovic T. Risk Factors for Hepatocellular Carcinoma: A Case-Control Study in Belgrade (Serbia). Tumori Journal 2018;96:911-7. [DOI: 10.1177/548.6508] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
550 Di Maso V, Mediavilla MG, Vascotto C, Lupo F, Baccarani U, Avellini C, Tell G, Tiribelli C, Crocè LS. Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis. PLoS One 2015;10:e0143289. [PMID: 26624999 DOI: 10.1371/journal.pone.0143289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
551 Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, Ma F, Huang W, Yu L, Yue W, Wang Z, Li P, Zhang Y, Liang R, Wei Z, Cui Y, Xie W, Cai M, Yu X, Yuan Y, Xia X, Zhang X, Yang H, Qiu W, Yang J, Gong F, Chen M, Shen H, Lin D, Zeng Y, He F, Zhou G. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010;42:755-8. [DOI: 10.1038/ng.638] [Cited by in Crossref: 243] [Cited by in F6Publishing: 240] [Article Influence: 20.3] [Reference Citation Analysis]
552 Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, Li J, Ehman RL. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? Radiology. 2014;273:88-98. [PMID: 24893048 DOI: 10.1148/radiol.14132592] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
553 Iyer SC, Gopal A, Halagowder D. Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma. Mol Cell Biochem 2015;407:223-37. [PMID: 26104578 DOI: 10.1007/s11010-015-2471-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
554 Pang R, Lee TK, Poon RT, Fan ST, Wong KB, Kwong YL, Tse E. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology. 2007;132:1088-1103. [PMID: 17383430 DOI: 10.1053/j.gastro.2006.12.030] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 5.6] [Reference Citation Analysis]
555 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16(4): 418-424 [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 110] [Article Influence: 9.3] [Reference Citation Analysis]
556 Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 2007;72 Suppl 1:132-138. [PMID: 18087194 DOI: 10.1159/000111719] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
557 Shah ZK, McKernan MG, Hahn PF, Sahani DV. Enhancing and expansile portal vein thrombosis: value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic lesions. AJR Am J Roentgenol 2007;188:1320-3. [PMID: 17449777 DOI: 10.2214/AJR.06.0134] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
558 Alam S, Ahmad N, Mustafa G, Alam K, Khan M. Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced. Saudi J Gastroenterol 2008;14:15-9. [PMID: 19568488 DOI: 10.4103/1319-3767.37796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
559 Young RS, Aldiwani M, Hakeem AR, Nair A, Guthrie A, Wyatt J, Treanor D, Morris-Stiff G, Jones RL, Prasad KR. Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford). 2013;15:418-427. [PMID: 23458127 DOI: 10.1111/hpb.12008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
560 Kumar R, Goh BG, Kam JW, Chang PE, Tan CK. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. Clin Mol Hepatol 2020;26:196-208. [PMID: 31914720 DOI: 10.3350/cmh.2019.0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
561 Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol 2017;10:707-16. [PMID: 28460547 DOI: 10.1080/17512433.2017.1323633] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]